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Astrocytes are integral components of glutamatergic neurotransmission, providing 
essential metabolic processes for neuronal homeostasis and acting as the first line of 
defense against xenobiotics crossing the blood brain barrier. Arsenic is a xenobiotic with 
widespread natural and industrial prevalence, and has been linked to impaired 
neurodevelopment and neuronal death. Given the integrated metabolic nature of 
astrocytes and neurons, we sought to explore how arsenic impacts astrocyte metabolism 
in order to better understand the mechanisms of xenobiotic toxicity in the mammalian 
brain. 
 We demonstrate that astrocyte viability depends upon de novo glutathione (GSH) 
synthesis during arsenic exposure, and sub-lethal arsenic exposure (iAs <10µM) 
increased intracellular GSH. Multidrug resistance-associated protein 1 (MRP1) inhibition 
increased intracellular arsenic accumulation and sensitized the astrocytes to arsenic. A 
24hr time course of intracellular arsenic accumulation indicated that arsenic efflux is 
achieved 3hrs following exposure, demonstrating naive and adaptive phases.  
 U-13C-glucose NMR-based metabolomics revealed that iAs induced an 
anaplerotic generation of glutamate via the tricarboxylic acid cycle and its extracellular 
release in astrocytes. Quantification of the extracellular glutamate indicated potentially 
excitotoxic concentrations were reached (Glu > 20µM), which were not significantly 
altered by γ-glutamyl transpeptidase (γGT) or MRP1 inhibition. Excitatory amino acid 
transporter 1 and 2 (EAAT1/2) inhibition significantly increased extracellular glutamate 
accumulation even in the absence of arsenic. 
 Mitotoxins rotenone (Rote), paraquat (PQ), or 1-methyl-4-phenylpyridinium 
(MPP
+
) sensitized the astrocytes to arsenic. Inhibition of mitochondrial carbon inputs by 
etomoxir (Eto) or UK5099 (UK), or of transamination by aminooxyacetic acid (AOAA), 
sensitized astrocytes to arsenic to a similar degree. Eto, UK, and AOAA increased arsenic 
accumulation in astrocytes but did not significantly alter extracellular glutamate 
accumulation. 
 This thesis illustrates that mitochondrial metabolism is essential to astrocytes 
survival during xenobiotic exposure. Further, the significant efflux of glutamate may 
create toxic conditions for neurons. Astrocytes previously have been shown to be 
glycolytic, resistant to mitochondrial toxins, and viable in vivo without functional 
electron transport chain. These results now demonstrate that mitochondria metabolism is 
essential for astrocytes survival under conditions of stress and require us to reassess the 
role of mitochondrial metabolism in astrocytes. 
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CHAPTER 1 
INTRODUCTION AND BACKGROUND INFORMATION 
 
 Xenobiotics are substances, compounds, or elements that are found at concentrations in 
an organism that are not expected to be there. The term xenobiotic is derived from the Greek 
words xeno (foreign) and bios (life), and is often used as an encompassing term for anything toxic 
to an organism. It should be noted however that xenobiotics are context specific: while the 
mitochondrial toxin rotenone is considered a xenobiotic in a mammalian system, it is not 
considered a xenobiotic when found within legumes that produce it unless the concentration of 
rotenone greatly exceeds the expected concentrations found within that specie. In humans, 
environmental xenobiotic exposure has been linked to a variety of neurodegenerative diseases and 
irregular neurodevelopment, such as Parkinson’s Disease and Alzheimer’s Disease (see (Bondy, 
2016) and (Rock and Patisaul, 2018) for more details). As xenobiotic toxicants are prevalent in 
our environment, it is important to understand their effects in order to better treat the symptoms 
of their toxicity, particularly when the effects of chronic exposure are not readily observable. 
 Arsenic is a group 15 metalloid element that is considered a xenobiotic to the mammalian 
system and has a widespread and varied natural distribution within the Earth’s crust. Arsenic is 
also found in many industrial settings, including waste products from metal smelting, as an n-type 
dopant in semiconductors, as a component of alloys and batteries, and as a wood preservative. 
Additionally, the toxic properties of arsenic have been exploited in herbicides, pesticides, and 
leukemia treatment. Arsenic exposure in humans primarily occurs through ingestion of arsenic 
contaminated water or food, and inhalation of arsenic dust, particularly in industrial settings. 
Arsenic is highly water soluble, and groundwater sources can be highly contaminated from 
natural, industrial, and/or agricultural sources (Nordstrom, 2002;Duker et al., 2005). The danger 
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that can occur from arsenic contaminated water was highlighted during the 1980s in Bangladesh, 
where ground water wells created to provide clean water to the population were years later found 
to contain high concentrations of arsenic (for an in depth review, see (Chakraborti et al., 2015)). 
At the time of assessment, it was estimated that 21 million people had been exposed to water with 
arsenic above 50 µg/L (the maximum permissible limit by the World Health Organization 
(WHO)), with twice as many above 10 µg/L (the recommended WHO limit, and the limit adopted 
by the United States in 2001) (Smith et al., 2000). In 2011, an approximate 43,000 deaths/year in 
Bangladesh (5.6% of all deaths) were attributable to arsenic related poisoning and cancers (Sohel 
et al., 2009;Flanagan et al., 2012), highlighting the danger of arsenic contamination. Further, in 
2010 an estimated 2.1 million Americans are consuming water from wells above the 10 µg/L 
limit of the Environmental Protection Agency (EPA). 
 Arsenic exposure has been found to negatively impact neurodevelopment. Multiple 
inverse correlations have been found between intelligence quotient (IQ) parameters and 
environmental arsenic exposure during childhood (Rosado et al., 2007;Dong and Su, 
2009;Hamadani et al., 2011;Wasserman et al., 2014). Many studies have focused on the effects of 
arsenic on neurons, demonstrating neuronal cell death, dysfunction, and malformation during 
arsenic exposure in development (Namgung and Xia, 2001;Chattopadhyay et al., 
2002a;Chattopadhyay et al., 2002b;Wang et al., 2010;Kaler et al., 2013). The mitochondria of 
neurons are particularly affected by arsenic exposure, which is a prominent source of neuronal 
cell death given neuronal dependence upon oxidative phosphorylation (see (Prakash et al., 2016) 
for a review, as well as chapters 2 and 3). While the effects of arsenic on neurons have been 
extensively studied, far less research has been directed towards the effects of arsenic on the 
astrocytes. As reviewed in more detail in chapters 2 and 3, astrocytes envelope the brain 
capillaries with their processes, making them the first cell type to contact toxins capable of 
passing the blood brain barrier, such as arsenic. Further, astrocytes have a cooperative 
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metabolism with neurons, maintain neuronal REDOX homeostasis, neurotransmitter homeostasis 
and clearance, and provide neurons with bioenergetic balance with lactate (see chapter 3). A key 
aspect of astrocytes is that they are glycolytic, and do not depend on oxidative phosphorylation 
(Supplie et al., 2017). This makes astrocytes far more resistant to mitochondrial poisons 
compared to their neuronal counterparts (Bolanos et al., 1995;Almeida et al., 2001), and has led 
to the astrocyte mitochondria in particular being understudied in xenobiotic toxicity.  
 Because neurons and astrocytes are highly interconnected cell types, and disruption of 
astrocyte functions can impact neurons and neurotransmission, it is important to understand how 
a xenobiotic, such as arsenic, impacts the functions of astrocytes to understand how xenobiotics 
affect brain functions. This thesis will begin with a review of central nervous system cell types 
and signaling, transition into astrocyte metabolic functions with an emphasis on mitochondria, 
and conclude with experiments performed to explore how arsenic affects astrocyte metabolism. 
The results show the astrocyte is dependent upon de novo glutathione synthesis and multidrug 
resistance protein 1 functions during arsenic exposure. Further, the results indicate a shift in 
astrocyte metabolism toward the production and extrusion of excitotoxic concentrations of 
glutamate, and demonstrate the astrocyte is dependent upon mitochondrial carbon flux, 
transamination, and excitatory amino acid transporter 1 activity during arsenic exposure. 
  
 
 
 
 
 
 
 
4 
 
1.1 References 
Almeida, A., Almeida, J., Bolanos, J.P., and Moncada, S. (2001). Different responses of 
astrocytes and neurons to nitric oxide: the role of glycolytically generated ATP in 
astrocyte protection. Proc Natl Acad Sci U S A 98, 15294-15299. 
Bolanos, J.P., Heales, S.J., Land, J.M., and Clark, J.B. (1995). Effect of peroxynitrite on the 
mitochondrial respiratory chain: differential susceptibility of neurones and astrocytes in 
primary culture. J Neurochem 64, 1965-1972. 
Bondy, S.C. (2016). Anthropogenic pollutants may increase the incidence of neurodegenerative 
disease in an aging population. Toxicology 341-343, 41-46. 
Chakraborti, D., Rahman, M.M., Mukherjee, A., Alauddin, M., Hassan, M., Dutta, R.N., Pati, S., 
Mukherjee, S.C., Roy, S., Quamruzzman, Q., Rahman, M., Morshed, S., Islam, T., Sorif, 
S., Selim, M., Islam, M.R., and Hossain, M.M. (2015). Groundwater arsenic 
contamination in Bangladesh-21 Years of research. J Trace Elem Med Biol 31, 237-248. 
Chattopadhyay, S., Bhaumik, S., Nag Chaudhury, A., and Das Gupta, S. (2002a). Arsenic 
induced changes in growth development and apoptosis in neonatal and adult brain cells in 
vivo and in tissue culture. Toxicol Lett 128, 73-84. 
Chattopadhyay, S., Bhaumik, S., Purkayastha, M., Basu, S., Nag Chaudhuri, A., and Das Gupta, 
S. (2002b). Apoptosis and necrosis in developing brain cells due to arsenic toxicity and 
protection with antioxidants. Toxicol Lett 136, 65-76. 
Dong, J., and Su, S.Y. (2009). The association between arsenic and children's intelligence: a 
meta-analysis. Biol Trace Elem Res 129, 88-93. 
Duker, A.A., Carranza, E.J., and Hale, M. (2005). Arsenic geochemistry and health. Environ Int 
31, 631-641. 
Flanagan, S.V., Johnston, R.B., and Zheng, Y. (2012). Arsenic in tube well water in Bangladesh: 
health and economic impacts and implications for arsenic mitigation. Bull World Health 
Organ 90, 839-846. 
Hamadani, J.D., Tofail, F., Nermell, B., Gardner, R., Shiraji, S., Bottai, M., Arifeen, S.E., Huda, 
S.N., and Vahter, M. (2011). Critical windows of exposure for arsenic-associated 
impairment of cognitive function in pre-school girls and boys: a population-based cohort 
study. Int J Epidemiol 40, 1593-1604. 
Kaler, S., Dhar, P., Bhattacharya, A., and Mehra, R.D. (2013). Preliminary morphological and 
immunohistochemical changes in rat hippocampus following postnatal exposure to 
sodium arsenite. Toxicol Int 20, 160-169. 
Namgung, U., and Xia, Z. (2001). Arsenic induces apoptosis in rat cerebellar neurons via 
activation of JNK3 and p38 MAP kinases. Toxicol Appl Pharmacol 174, 130-138. 
Nordstrom, D.K. (2002). Public health. Worldwide occurrences of arsenic in ground water. 
Science 296, 2143-2145. 
Prakash, C., Soni, M., and Kumar, V. (2016). Mitochondrial oxidative stress and dysfunction in 
arsenic neurotoxicity: A review. J Appl Toxicol 36, 179-188. 
Rock, K.D., and Patisaul, H.B. (2018). Environmental Mechanisms of Neurodevelopmental 
Toxicity. Curr Environ Health Rep 5, 145-157. 
Rosado, J.L., Ronquillo, D., Kordas, K., Rojas, O., Alatorre, J., Lopez, P., Garcia-Vargas, G., Del 
Carmen Caamano, M., Cebrian, M.E., and Stoltzfus, R.J. (2007). Arsenic exposure and 
cognitive performance in Mexican schoolchildren. Environ Health Perspect 115, 1371-
1375. 
Smith, A.H., Lingas, E.O., and Rahman, M. (2000). Contamination of drinking-water by arsenic 
in Bangladesh: a public health emergency. Bull World Health Organ 78, 1093-1103. 
5 
 
Sohel, N., Persson, L.A., Rahman, M., Streatfield, P.K., Yunus, M., Ekstrom, E.C., and Vahter, 
M. (2009). Arsenic in drinking water and adult mortality: a population-based cohort study 
in rural Bangladesh. Epidemiology 20, 824-830. 
Supplie, L.M., Duking, T., Campbell, G., Diaz, F., Moraes, C.T., Gotz, M., Hamprecht, B., 
Boretius, S., Mahad, D., and Nave, K.A. (2017). Respiration-Deficient Astrocytes 
Survive As Glycolytic Cells In Vivo. J Neurosci 37, 4231-4242. 
Wang, X., Meng, D., Chang, Q., Pan, J., Zhang, Z., Chen, G., Ke, Z., Luo, J., and Shi, X. (2010). 
Arsenic inhibits neurite outgrowth by inhibiting the LKB1-AMPK signaling pathway. 
Environ Health Perspect 118, 627-634. 
Wasserman, G.A., Liu, X., Loiacono, N.J., Kline, J., Factor-Litvak, P., Van Geen, A., Mey, J.L., 
Levy, D., Abramson, R., Schwartz, A., and Graziano, J.H. (2014). A cross-sectional 
study of well water arsenic and child IQ in Maine schoolchildren. Environ Health 13, 23. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6 
 
CHAPTER 2 
MITOCHONDRIAL DYSFUNCTION IN GLIAL CELLS: IMPLICATIONS FOR 
NEURONAL HOMEOSTASIS AND SURVIVAL 
(Published November 1 2017 in Toxicology, Vol. 391:109-115) 
2.1 Introduction 
 Mitochondria are involved in a myriad of other processes relevant for cell function 
besides energy (ATP) production (Yin et al., 2014), making them more than simply powerhouses 
of the cell. Mitochondria are a hub for signaling processes that include the maintenance of 
calcium (Ca
2+
) homeostasis and the formation of signaling molecules and thus, signaling events 
(Bonini;Chandel, 2015).  For example, cell death progression is well known to be triggered by the 
release of mitochondrial pro-death proteins.  Alterations in mitochondrial functions are expected 
to have important implications for cellular function and disease progression. Correspondingly, 
numerous pathological conditions have been connected to mitochondrial dysfunction. 
 Neuronal cell death in brain disorders (neurodegeneration) and injury (neurotoxicity and 
ischemia) has been linked to a variety of alterations in mitochondrial homeostasis/function 
including traffic, quality control and turnover, homeostasis (bioenergetics and electron transport)  
and signaling (metabolism and Ca
2+
 handling) (Chaturvedi and Flint Beal, 2013;Yin et al., 2014). 
Compared to other cell types, neurons are more dependent on mitochondrial oxidative 
phosphorylation (OXPHOS) to fulfill their energy demands. Mitochondrial dysfunction with the 
concomitant energy failure and increased generation of reactive oxygen species (ROS) are 
considered central to neuronal cell loss in brain disorders because neurons have a limited capacity 
to upregulate glycolysis or to counteract oxidative damage (Herrero-Mendez et al., 
2009;Fernandez-Fernandez et al., 2012). As such, research has been primarily directed at 
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understanding the causes and consequences of mitochondrial dysfunction in neuronal populations 
affected during neurodegeneration or brain injury (Moran et al., 2012;Yin et al., 2014). 
 While initially considered as accessory cells to neurons, glial cells are now recognized to 
be essential for neuronal cell homeostasis, survival and proper brain function and development 
(Fernandez-Fernandez et al., 2012;Kubik and Philbert, 2015;Bolanos, 2016). Importantly, genetic 
modifications or xenobiotics (i.e. pesticides [rotenone or paraquat], metals [lead, arsenic], 
antibiotics and drugs that target the integrity of mitochondrial DNA) recognized to alter 
mitochondrial function in neurons are expected to alter mitochondrial function in glial cells as 
well (Ballinger;Chan;Meyer et al., 2013;Kubik and Philbert, 2015). Unfortunately, very few 
studies have addressed the pathological implications of mitochondrial dysfunction in glial cells 
and its consequences in neurological disorders. Herein, we review the current evidence 
demonstrating the importance of mitochondrial homeostasis and signaling in glial function and 
how their functional deficiency has important implications for brain disorders and injury that lead 
to or are a consequence of neuronal cell death. 
2.2 Glial cell types and their functional roles 
 Glial cells can be generally classified as macroglia (astrocytes and oligodendrocytes) or 
microglia. Macroglia originate from the embryonic ectoderm, while microglia originate from the 
mesoderm and enter the vertebrate brain during embryogenesis. While initially grouped under the 
term “glia” (Greek term for glue), it is now clearly established that glial cells regulate a number 
of physiological processes required for proper neuronal survival and brain function. Refinement 
and revision of counting techniques have demonstrated that while the overall ratio of neurons to 
glial varies between different regions in the brain, a ratio of ~1:1 glia to neuron exists in the 
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Figure 2.1 Neuronal metabolism, redox homeostasis and signaling are supported by neighboring glial 
cells.  
(1.1) Glucose and lactate enter the brain through Glut1 (glucose transporter 1) and MCT1 
(monocarboxylate transporter 1) transporters in the vascular epithelium. Glucose (Glut3) and lactate 
(MCT1 or 2) are uptaken from the extracellular space by neuronal calls to fuel the TCA cycle for the 
generation of ATP and biosynthesis of essential molecules.  
(1.2) As a component of the blood brain barrier (BBB), astrocytes uptake glucose from the capillary 
epithelium via Glut1 as well, converting the majority of pyruvate (Pyr) generated into lactate which is 
exported by MCT1. Astrocytes also uptake the neurotransmitter glutamate (Glu) from the synaptic cleft via 
EAAT (excitatory amino acid transporters) to be (a) converted into glutamine (Gln), (b) exchanged for 
extracellular cystine (Cys) by xCT, (c) feed into the TCA cycle, or (d) for GSH synthesis. Astrocytes form  
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(Figure 2.1 Neuronal metabolism, redox homeostasis and signaling are supported by neighboring glial 
cells continued)  
extended networks with other glia (oligodendrocytes and astrocytes) via gap junctions, sharing nutrients 
and molecular components with cells more distal to the capillaries.  
(1.3) Astrocytes contribute to the redox state of neuronal cells by exporting GSH via MRP1 which is 
broken down by γGT and ApN into its amino acid components to be uptaken and reassembled as GSH in 
neuronal cells. Dysfunctional or damaged mitochondrial, likely capable of generating ROS, are transferred 
from neurons to astrocytes to be degraded by mitophagy.  
(1.4) Oligodendrocytes wrap neuronal projections (myelin sheaths) improving signal conduction and like 
astrocytes, have been proposed to shuttle lactate to the neurons.  
(1.5) Microglia are activated by a variety of factors, including cytokines, oxidized proteins, and protein 
aggregates. Activated microglia migrate to the site of damage and can induce neuronal or oligodendrocyte 
cell death through the release of cytokines, and the generation of ROS via NADPH oxidases (NOX) and 
nitric oxide synthases (NOS). AA-T, amino acid transporters; LDH1 or 5, lactate dehydrogenase isoform 1 
or 5. 
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entire human brain, which is significantly smaller than previous estimates (~10:1). 
Oligodendrocytes are reported to be the most abundant type of glial cells (45–75%), followed by 
astrocytes (19–40%), and microglia (10% or less) (von Bartheld et al., 2016). 
 Oligodendrocytes are responsible for axon myelination at large membrane extensions, 
providing axons with an “insulating coat” that enhances nerve impulse conduction (Figure 2.1.4). 
Oligodendrocytes have several extensions that form several internodal segments of myelin 
separated by gaps (Ranvier nodes) (Baumann and Pham-Dinh, 2001;Snell, 2010). 
Oligodendrocytes are found in both gray and white matter, but are a major fraction of all the cells 
in white matter.  
 Astrocytes are small cells with processes that are radially arranged, and have 
considerable molecular, structural, and functional diversity at the regional level. Astrocyte 
extensions cover the external surface of brain capillaries (perivascular feet), the synaptic cleft 
between the pre-synaptic and the post-synaptic terminals, and the bare segments of axons at the 
Ranvier nodes (Figure 2.1.2). Astrocytes also form highly organized domains interconnected via 
gap junctions with other astrocytes and oligodendrocytes (Figure 2.1.2). Additionally, astrocytes 
regulate neurotransmitter levels in the synaptic cleft, provide neurons with energetic and 
antioxidant precursors (Figure 2.1.2), play an important role in neuro/synaptogenesis and tissue 
repair, and also regulate blood flow and inflammatory processes by the release of signaling 
mediators (Sofroniew and Vinters, 2010).  
 Microglial cells are resident macrophages distributed throughout the central nervous 
system (CNS) (Byrne and Roberts, 2009). As innate immune cells, microglia are activated by 
infection, tissue injury, or xenobiotics. Upon activation, microglia cells retract their cytoplasmic 
extensions and migrate to the site of injury, where they proliferate and become antigen presenting 
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cells. Microglia phagocytose degenerating cells and act as sources of immunoregulatory and 
neuromodulatory factors such as cytokines, chemokines and neurotrophic factors. Microglia can 
be activated by cell-surface receptors for endotoxins, cytokines, chemokines, misfolded proteins, 
serum factors and ATP (Figure 2.1.5). While mild activation is a key adaptive immune response, 
continuous activation or overactivation of microglia is thought to contribute to neurodegeneration 
(Hanisch and Kettenmann, 2007;Finsen and Owens, 2011;Hanisch, 2013).  
2.3 Mitochondrial dysfunction in glial cells and its effect on neuronal function/survival 
2.3.1 Cell death 
 Apoptosis is a ubiquitous homeostatic mechanism critical for the turnover of cells 
throughout the lifespan of multi-cellular organisms.  However, dysregulation of apoptosis occurs 
as either a cause or consequence of distinct pathologies that include neurodegenerative disorders 
(Fadeel and Orrenius, 2005). The signaling pathways that regulate the progression of apoptosis 
have been extensively characterized and divided in two pathways. Induction of apoptosis via the 
extrinsic pathway is triggered by the activation of the death receptors leading to the activation of 
initiator caspases. (Lavrik et al., 2005). 
 The intrinsic mitochondrial pathway of apoptosis is activated by a wide variety of stimuli 
that regulate the expression and function of the Bcl-2 (B-cell lymphoma 2) family of (anti or pro) 
apoptotic proteins. The BH3-only Bcl-2 family members (Bad, Bid, Bim and NOXA) regulate the 
anti-apoptotic Bcl-2 proteins (Bcl-2, Bcl-xl and Mcl-1) to promote apoptosis. The pro-apoptotic 
effector proteins Bax and Bak are sufficient and necessary for inducing the permeabilization of 
the outer mitochondrial membrane and the release of Cyt C (Figure 2.2.6). However, the 
activation of BH3-only proteins derepresses the direct inhibition of Bax and Bak by anti- 
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Figure 2.2 Mitochondrial metabolism and signaling in astrocytes.  
(2.1) Glucose in astrocytes is used for glycogenesis, NADPH production through the PPP, or glycolysis. 
Astrocytes are highly glycolytic due to the expression of high levels of 6‐phosphofructo‐2‐kinase / 
fructose‐2,6‐bisphosphatase‐3 (PFKFB3), whose byproduct fructose‐2,6‐bisphosphate (F2,6P2), is a 
positive effector of the glycolytic enzyme 6‐phosphofructo‐1‐kinase (PFK1). In addition, the activity of 
PFKFB3 is increased by phosphorylation by 5′‐AMP‐activated protein kinase (AMPK) (Bolanos, 2016).  
(2.2) Astrocytes primarily derive ATP from glycolysis rather than oxidative phosphorylation, where 
pyruvate is converted to lactate by LDH5 and exported to the extracellular space to be consumed by 
neurons.  
 
13 
 
(Figure 2.2 Mitochondrial metabolism and signaling in astrocytes continued)  
(2.3) Astrocytes carboxylate pyruvate to oxaloacetate (OAA) via pyruvate carboxylase (PC) to regenerate 
TCA cycle intermediates. Phosphorylation of pyruvate dehydrogenase (PDH) restricts the conversion of 
pyruvate to acetyl-CoA (Ac-CoA). Thus, FAO has been proposed to be the primary contributor of Ac-CoA 
to the TCA cycle.  
(2.4) α-ketoglutarate (αKG) generated from the TCA cycle can be transported to the cytosol and converted 
to Glu by glutamic-oxaloacetic transaminase 1 or aspartate (Asp) aminotransferase (GOT1) as part of the 
malate-Asp shuttle. Glu has three central metabolic pathways in astrocytes. 1) Glu can be converted to Gln 
by GS and exported to neurons by the sodium-coupled neutral amino acid transporter 3 (SNAT3). 2) Glu is 
exchanged via xCT for extracellular cystine that is reduced to Cys. Extracellular Glu can be uptaken back 
by astrocytes by EAAT1/2. Finally, 3) Glu, Gly and Cys are precursors of GSH, which is also exported to 
neurons via MRP1.  
(2.5) The ER acts as a store for intracellular calcium, where the sarco/endoplasmic reticulum calcium ion 
ATPase (SERCA) pumps cytosolic Ca
2+
 into the ER. Ca
2+
 signaling is tightly regulated by the activation of 
IP3R that release Ca
2+
 from ER stores, as well as by the activation of plasma membrane Ca
2+
 channels. 
Mitochondria can buffer Ca
2+
 by its transport across the inner mitochondrial membrane to the matrix via 
MCU), while the export is performed by mNCX and mHCX. Mitochondria can also transport Ca
2+
 in and 
out of the mitochondria via the activation of distinct Ca
2+
 permeable channels. In the matrix, Ca
2+
 
stimulates TCA carbon flux by binding to PDH, IDH, and αKGDH, increasing the activity of the ETC and 
ATP production.  
(2.6) Cyt C is held close to the inner mitochondrial membrane by cardiolipin (not shown), acting as a 
component of ETC. Dissociation of Cyt C from cardiolipin, through oxidative or enzymatic means, coupled 
with permeabilization of the outer mitochondrial membrane by the formation of Bax/Bak oligomeric 
channels, allows Cyt C to escape into the cytosol. Cytosolic Cyt C associates with apoptotic protease- 
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(Figure 2.2 Mitochondrial metabolism and signaling in astrocytes continued)  
activating factor 1 (APAF1), forming the apoptosome and leading to the activation of caspases to initiate 
apoptosis. AGC, aspartate-glutamate carrier; CPT1 or 2, carnitine palmitoyltransferase isoform 1 or 2; 
MDH1 or 2, malate dehydrogenase isoform 1 or 2; MPC1, mitochondrial pyruvate carrier 1; OGC, 2-
oxoglutarate (α-ketoglutarate) carrier. 
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apoptotic Bcl-2 proteins. Released Cyt C leads to the recruitment of Apaf1 and caspase 9 into a 
platform (apoptosome) that activates caspase 9 and subsequently, executioner caspases 3, 6 and 7. 
The extrinsic / death receptor pathway can crosstalk to the intrinsic / mitochondrial pathway of 
apoptosis by an amplification loop induced by caspase dependent cleavage/activation of Bid 
(Green and Llambi, 2015). 
 While a number of studies have reported the induction of apoptosis in astrocytes and 
microglia under different experimental conditions, very little evidence exists about the loss or 
degeneration of these glial cells with respect to human disorders. Conversely, oligodendrocytes 
are known to degenerate in demyelinating disorders such as multiple sclerosis, and to be affected 
directly or indirectly by the majority of known disorders in the CNS including ischemia, trauma 
and neurodegeneration. Glutamate/Ca
2+
 excitotoxicity, inflammation (cytokines) and oxidative 
stress are common triggers for oligodendrocyte injury in these pathological situations (Figure 
2.1.4). Oligodendrocytes express ionotropic α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic 
acid (AMPA)/kainite receptors whose activation induces Ca
2+
 overflow and apoptotic cell death 
via the intrinsic mitochondrial pathway via activation of Bax and caspase 3 (Figure 2.1.4) (Ruiz 
et al., 2010;Sanchez-Gomez et al., 2011). The high lipid and iron content of oligodendrocytes 
also makes them susceptible to oxidative damage induced by cytokines (Zhang et al., 2005). 
2.3.2 Bioenergetics and metabolism 
 Neurons are dependent on high rates of OXPHOS to meet their energy requirements, to 
maintain and restore ionic gradients, and for the uptake and recycling of neurotransmitters.  In 
contrast, astrocytes are highly glycolytic (Figure 2.2.1), but a large portion of glucose is 
converted to lactate and released to the extracellular space. Interestingly, glucose consumption in 
astrocytes exceeds their energy expenditure, which is explained by the astrocytes-neuron lactate 
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shuttle hypothesis where lactate is shuttled from astrocytes (and oligodendrocytes) as a fuel for 
OXPHOS in neurons (Figure 2.1.1 and 2.2.2) (Belanger et al., 2011;Funfschilling et al., 
2012a;Lee et al., 2012;Morrison et al., 2013).  What limits OXPHOS in astrocytes? Recent 
studies have demonstrated that the activity of pyruvate dehydrogenase (PDH), which provides a 
route of entry for pyruvate into the tricarboxylic acid (TCA or Krebs) cycle, is reduced by its 
phosphorylation in astrocytes (Figure 2.1.1 and 2.2.3) (Halim et al., 2010). Interestingly, 
astrocytes have the same oxidative capacity as neurons, but are resilient to mitochondrial 
dysfunction (Di Monte et al., 1992).   
 Other carbon sources can fuel OXPHOS in astrocytes. Glutamate can be metabolized 
through the TCA cycle, but astrocytes primarily metabolize it to glutamine by the activity of 
glutamine synthase (GS) (Figure 2.2.4). However, when the extracellular concentration of 
glutamate increases to levels observed during synaptic transmission, the proportion of glutamate 
metabolized by the TCA cycle increases as well, while its conversion to glutamine decreases 
concomitantly (McKenna, 2013;Schousboe et al., 2014;Nissen et al., 2015). Importantly, 
glutamate also exerts a stimulatory effect on glycolysis as well (Pellerin and Magistretti, 
1994;Loaiza et al., 2003). 
 Acetate is also used as a carbon source by astrocytes, but its physiological significance 
has not been established (Belanger et al., 2011;Jiang et al., 2013). Astrocytes can oxidize free 
fatty acids (FFA) and ketone bodies, but neurons and oligodendrocytes can only use ketone 
bodies as these cell types would be highly vulnerable to ROS formation generated by FFA 
oxidation due to their high lipid content (Schonfeld and Reiser, 2013;Iglesias et al., 2016). 
Twenty percent of total energy expenditure in the brain is linked to FFA oxidation (FAO), which 
occurs primarily in astrocytes (Ebert et al., 2003). As mentioned above, astrocytes exhibit high 
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rates of OXPHOS (Lovatt et al., 2007), but a larger proportion of astrocyte PDH is 
phosphorylated compared to neuronal PDH, inhibiting the conversion of pyruvate to acetyl-CoA 
(Halim et al., 2010). Thus, FAO might actually be a major source for acetyl-CoA into the TCA 
cycle (Panov et al., 2014) (Figure 2.2.3). 
 Oligodendrocytes have similar rates of glycolysis compared to astrocytes, but release less 
lactate since a larger proportion of pyruvate derived from glucose is metabolized via PDH into 
the TCA cycle. Similar to astrocytes, oligodendrocytes can carboxylate pyruvate to oxaloacetate 
via pyruvate carboxylase (PC) to replenish TCA intermediates (anaplerosis) or recycle pyruvate 
(Figure 2.2.3) (Amaral et al., 2016). In astrocytes however, pyruvate carboxylation also serves to 
compensate for the loss of TCA intermediates due to the generation of glutamate and 
subsequently glutamine that is then shuttled to neurons (glutamate-glutamine cycle) (Figure 2.1.2 
and 2.2.4) (Schousboe et al., 2014). Lactate metabolism in oligodendrocytes has been 
demonstrated to participate in oligodendrocyte differentiation and myelination.(Rinholm et al., 
2011). Importantly, mitochondrial respiration / metabolism seems to be primarily involved in 
oligodendrocyte differentiation, while glycolysis appears to be sufficient to maintain post-
myelinated (differentiated) oligodendrocytes (Funfschilling et al., 2012b). Accordingly, 
demyelination disorders linked to mitochondrial dysfunction seem to be primarily linked to 
increased oxidative damage and changes in FFA metabolism but not energy failure (Swalwell et 
al., 2011;Lin et al., 2012;Viader et al., 2013). 
2.3.3 Calcium 
 Calcium (Ca
2+
) signaling is tightly coupled to its homeostasis. Ca
2+
 gradients across 
membranes and cellular compartments are established by the activity of Ca
2+
 pumps / 
transporters. The controlled activation of Ca
2+
 fluxes allows its release and the subsequent 
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activation of a diverse array of signal transducers including kinases, enzymes and ion channels. 
Mitochondria are now recognized as important Ca
2+
 reservoirs or sinks. The regulation of Ca
2+
 
signaling is not a simple process of its release and subsequent compartmentalization. Instead, it 
involves a highly localized release and controlled diffusion of Ca
2+
 across intracellular 
compartments and in most cases, the coordinated action of more than one Ca
2+
 reservoir and 
release / uptake system. The spatiotemporal complexity of this process is reflected by the 
existence of patterns of Ca
2+
 waves or sparks that are decoded by transducers selectively localized 
in different cellular compartments. Sequestration of Ca
2+
 within the mitochondrial matrix is 
partially driven by the negative environment generated by the extrusion of protons (H
+
) across the 
inner mitochondrial membrane by the ETC (Figure 2.2.3). Translocation of Ca
2+
 into the matrix 
is mediated by the mitochondrial Ca
2+
 uniporter (MCU) in an energy-independent manner 
(Figure 2.2.5). Ca
2+
 release from the mitochondria is mediated by Ca
2+
 exchangers (the sodium 
[Na
+
)]/Ca
2+
 [mNCX] and mitochondrial proton [H
+
]/Ca
2+
 exchangers [mHCX]), or the opening of 
the mitochondrial permeability transition pore under pathological conditions (Figure 2.2.5). 
Importantly, mitochondria act as important buffers for Ca
2+
 release / influx from the endoplasmic 
reticulum (ER) and the plasma membrane that contribute to the regulation of Ca
2+
 signaling 
(Figure 2.2.5) (Rizzuto et al., 2012). 
 Very little is known about the impact of mitochondrial Ca
2+
 homeostasis on glial 
signaling. However, as in other cell types, functional mitochondria in astrocytes and 
oligodendrocytes regulates Ca
2+
 waves generated by the activation of inositol 1,4,5-triphosphate 
(IP3) receptors (IP3R) and the release of Ca
2+
 from the ER (Simpson and Russell, 1996;Boitier et 
al., 1999;Smith et al., 2005). Mitochondrial Ca
2+
 has also been shown to regulate vesicular 
glutamate release from astrocytes that modulates synaptic communication and excitability (Reyes 
and Parpura, 2008). Ca
2+
 accumulation in mitochondria also modulates oxidative phosphorylation 
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and energy production. PDH activity is regulated by a Ca
2+
-dependent dephosphorylation, while 
Ca
2+
 binding also regulates α-ketoglutarate (KGDH)- and isocitrate (IDH)-dehydrogenase 
activity, which  increases NADH levels, electron flow and ATP synthesis (Figure 2.2.5) (Rizzuto 
et al., 2012). Accordingly, Ca
2+
 release from the ER stimulates mitochondrial-dependent energy 
production in astrocytes (Wu et al., 2007). Not only do mitochondria regulate Ca
2+
 accumulation 
and dynamics, but also its release. A recent report demonstrated that Ca
2+
 release via mNCX is 
coupled to store-operated Ca
2+
 entry (triggered by Ca
2+ 
depletion from ER stores) and regulates 
astrocytes proliferation and excitotoxic glutamate release (Parnis et al., 2013). In microglia, 
mitochondrial Ca
2+
 influx via the mitochondrial transient receptor potential vanilloid 1 channel 
(TRPV1) depolarizes mitochondria resulting in mtROS production, mitogen activated protein 
kinase (MAPK) activation, and enhanced migration (Miyake et al., 2015). 
2.3.4 Inflammation 
 Inflammation is a key contributor to most neurological disorders. In a steady “basal” 
state, microglia performs continuous surveillance of the CNS, secrete neurotrophic factors, such 
as insulin-like growth factor 1 (IGF1), brain-derived neurotrophic factor (BDNF), transforming 
growth factor-β (TGFβ) and nerve growth factor (NGF), and promote synapse pruning for 
refinement of neuronal circuits during development.  Classical activation of microglia (M1) 
conveys the production of ROS and nitrogen species (RNS) and the release of pro-inflammatory 
cytokines (tumor necrosis factor [TNF] and interleukin-1β [IL-1β]) to promote brain tissue repair 
upon injury (removal of cell debris and restoring of tissue integrity) and, upon prolonged 
activation, neuronal dysfunction as well. Disease-associated factors such as xenobiotics, protein 
aggregates, and damage (DAMPs) or pathogen-associated molecular patterns (PAMPS) can 
activate microglia through a variety of surface receptors. These receptors include Toll-like 
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receptors (for lipopolysacharide [LPS], oxidized low-density lipoprotein [LDL] and molecules 
released by damaged or dead cells including high-mobility group box 1 [HMGB1] and 
nucleotides), nucleotide-binding oligomerization domain (Nod)-like receptors (for amyloid 
proteins), advanced glycation end-products receptors or RAGE (that are also activated by 
HMGB1), and purinergic receptors (for purines and pyrimidines including nucleoside 
triphosphates, e.g. ATP) (Hu et al., 2014). Pro-inflammatory cytokines released from microglia 
also “activate” astrocytes, which might produce TNF to potentiate microglia activation as well. 
As such, co-cultures of microglia and astrocytes produce more neurotoxic factors than either 
activated cell type alone (Saijo and Glass, 2011). Whether astrocytes can be activated in the 
absence of microglia is still unclear since most studies using primary cultures of astrocytes also 
contain at least 5% of microglia that significantly contribute to astrocyte activation (Facci et al., 
2014;Marinelli et al., 2015). The alternative (M2-like) phenotype of microglia is observed to be 
induced by transforming growth factor-β (TGFβ), IL-4, IL-6 and IL-10 secreted from glioma cells 
(Saijo and Glass, 2011). 
 Mitochondrial dysfunction triggers inflammatory responses (West). During 
inflammation, changes in mitochondrial metabolism contribute to the activation of microglia. The 
M1 phenotype of microglia was recently reported to be paralleled by a metabolic switch from 
mitochondrial OXPHOS to glycolysis that enhances carbon flux to the PPP (Figure 2.1.5) 
(Voloboueva et al., 2013;Gimeno-Bayon et al., 2014;Orihuela et al., 2016). Interestingly, 
inhibition of complex I activity activates microglial cells (Shaikh and Nicholson, 2009;Yuan et 
al., 2013;Ye et al., 2016), while impairment of mitochondrial fission reduces the production of 
pro-inflammatory signals (Park et al., 2013). Induction of the M2-like phenotype results in no 
observable changes in mitochondrial oxygen consumption or lactate production (Orihuela et al., 
2016). However, mitochondrial toxins such as 3-nitropropionic acid and rotenone impair the 
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transition to the M2 phenotype induced by IL-4 (Ferger et al., 2010). These results suggest that 
mitochondrial dysfunction in microglia can exacerbate the pro-inflammatory M1 phenotype and 
result in the release of neurotoxic pro-inflammatory cytokines, and enhanced ROS / RNS 
formation (Tang and Le, 2016).  
2.3.5 Redox homeostasis and detoxification of xenobiotics 
 In general, neurons have limited defense mechanisms against ROS compared to 
astrocytes. This enhanced resistance to oxidative damage in astrocytes is observed despite the fact 
that astrocytes have a deficient mitochondrial respiration and increased ROS formation when 
compared to neurons (Lopez-Fabuel et al., 2016). A comparative study also demonstrated that 
astrocytes are more resistant to oxidative damage than microglia or oligodendrocytes 
(Hollensworth et al., 2000). Astrocytes contain higher levels of endogenous antioxidants and 
antioxidant systems that include NADPH and G6PD (glucose-6-phosphate dehydrogenase). 
Astrocytes’ resistance to oxidative damage is explained by the activation of the antioxidant 
response via the nuclear factor erythroid-2-related factor 2 (Nrf2) transcription factor (Garcia-
Nogales et al., 2003;Shih et al., 2003). Both neurons and astrocytes can synthesize GSH, but 
neurons depend on the supply of GSH precursors from astrocytes (Figure 2.1.3). GSH is released 
from astrocytes via the ATP-binding cassette transporters subfamily C member 1 transporter 
(ABCC1, or multidrug-resistance-associated protein 1 [MRP1]) (Hirrlinger and Dringen, 2005). 
Extracellular GSH is then degraded by the γ-glutamyl transpeptidase (γGT) to produce l-cysteine-
l-glycine (CysGly), which is cleaved further by the neuronal aminopeptidase N (ApN) into the 
amino acids glycine and cysteine that are taken up by neurons for de novo GSH synthesis (Figure 
2.1.3) (Aoyama et al., 2008;Belanger et al., 2011). The glutamate-glutamine cycle might also be 
involved in the regulation of the neuronal redox environment by astrocytes since GSH synthesis 
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also requires glutamate. The importance of astrocytes for neuronal redox homeostasis was 
evidenced by a recent study demonstrating that conditional depletion of astrocytes promotes 
neuronal injury by oxidative stress (Schreiner et al., 2015). Astrocytes are also the first line of 
defense against xenobiotics entering into the brain since their extensions cover the external 
surface of capillaries as part of the blood brain barrier. Detoxification of electrophiles is 
dependent the formation of irreversible adducts with GSH that in many cases depends on the 
activity of glutathione-S-transferases (GST) and their efflux through MRPs (Dringen et al., 2015). 
 But what is the role of mitochondria in redox homeostasis in astrocytes and neurons? The 
loss of GSH by its export to neurons or due to the detoxification of electrophiles is expected to 
prompt astrocytes to replenish GSH precursors. Interestingly, GSH depletion upregulates 
mitochondrial activity in astrocytes (Vasquez et al., 2001) and we have recently observed that 
mitochondrial OXPHOS is essential for the detoxification of electrophiles via the GSH/MRP 
system (manuscript in preparation), but the exact mechanisms that regulate this phenomenon are 
still unclear. 
2.4 Conclusions and Perspectives 
 Mitochondrial dysfunction has been widely recognized as central to the pathogenesis of 
neurological disorders. However, the majority of current research efforts have been focused on 
understanding the causes and consequences of mitochondrial dysfunction in neuronal cells that 
rely on OXPHOS to generate energy and are also more sensitive to mitochondrial ROS 
formation. Less is known about the functional role of mitochondria in glial cells and its 
implications for neuronal survival and brain function. In this work, we have provided an overview 
of the role of mitochondria in glial cell function that includes metabolism, redox homeostasis, 
Ca
2+
 signaling, inflammation and cell death. The evidence so far clearly demonstrates the 
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importance of mitochondrial health in glial cells and its relevance to neuronal function. 
Nevertheless, this review also highlights our limited understanding of mitochondria function in 
glial cells and the need for further investigations in this area that is expanding. For example, 
recent studies have demonstrated that damaged mitochondria can be transferred from neuronal 
axons for their turnover in astrocytes (Davis et al., 2014), and conversely, astrocytes have been 
shown to transfer mitochondria to promote neuronal survival (Hayakawa et al., 2016) (Figure 
2.1.3). Many questions remain to be answered regarding the role of mitochondrial in neurological 
disorders, but it is time for us to think about mitochondrial health and dysfunction in a more 
inclusive context outside neuronal cells. 
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CHAPTER 3 
MITOCHONDRIAL METABOLISM IN ASTROCYTES REGULATES BRAIN 
BIOENERGETICS, NEUROTRANSMISSION AND REDOX BALANCE 
 
3.1 Introduction 
 The central nervous system (CNS) is a complex, integrated structure composed of diverse 
cell types. Neurons are highly specialized cells in charge of transmitting, processing, and storing 
information and thus have been considered the functional units of the CNS. However, research 
within the last few decades has demonstrated critical roles non-neuronal cells play in CNS 
function. The non-neuronal cells of the CNS include macroglia (astrocytes, ependymal cells and 
oligodendrocytes) and microglia, which support essential functions such as the maintenance of 
neurotransmitter communication, metabolism, trophic support, formation of myelin sheath, 
wound healing, and immune surveillance (von Bernhardi et al., 2016) .  
 Astrocytes originate from the neuroectoderm. Recent estimates suggest they account for 
between 19-40% of the glial population (with an estimated glial to neuron ratio of ~1:1), and a 
strong regional variation within the CNS (von Bartheld et al., 2016). Astrocytes are a 
heterogenous population of cells with a diverse array of morphological, functional and molecular 
properties (Garcia-Marin et al., 2007). While the cellular identity of astrocytes is determined by 
their gene expression profile post-differentiation (intrinsic patterning) (Song et al., 2002;Krencik 
et al., 2011), the surrounding environment and neuronal circuitry further shapes, modifies, and 
maintains the form and functions of differentiated astrocytes (extrinsic factors) (Koulakoff et al., 
2008;Yang et al., 2009;Farmer et al., 2016;Ben Haim and Rowitch, 2017). Structurally, astrocytes 
contain multiple radial processes that create diverse interfaces with other glia, neurons, and 
capillary endothelial cells. Astrocytes’ fine processes and endfeet envelope neuronal cell bodies, 
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synapses, and blood vessels. In addition, an intracellular interface with other astrocytes or 
oligodendrocytes is generated via gap junctions (connexin channels), creating an extensive 
interconnected network throughout the brain (Orthmann-Murphy et al., 2008). Gap junctions 
exchange ions and small molecules between cells (<1kDa in size) including; inositol triphosphate 
(IP3), K
+
, Ca
2+
, ATP, glucose, glutamate, glutathione (GSH), and cyclic AMP; highlighting its 
signaling and buffering role within the CNS (Niessen et al., 2000;Goldberg et al., 2002;Bedner et 
al., 2006;Lapato and Tiwari-Woodruff, 2018).  
 Astrocytes are involved in a number of processes associated with brain function and 
disease progression.  Astrocytes are major secretory cells, releasing factors or transmitters 
(gliotransmitters) including neurotransmitters (and their precursors), modulators, peptides, 
hormones, trophic (growth) factors, and metabolites. Astrocyte secreted factors have been shown 
to be involved in synapse formation, function and plasticity, neuronal growth, differentiation and 
survival, as well as in the regulation of the vascular tone and blood flow in the brain. Astrocytes 
have also been shown to mediate synaptic pruning by phagocytosis (Chung et al., 2015;MacVicar 
and Newman, 2015;Verkhratsky et al., 2016).  
 Astrocytes become “reactive” as a response to pathological conditions or to perturbations 
in cellular homeostasis. Astrocyte reactivity is a loose term that primarily refers to an 
enlargement in the cell body and processes (hypertrophy), and an increase in the levels of the 
glial fibrillary acidic protein (GFAP), that relates to a pathological stimulus in the CNS. Unlike 
microglia, reactive astrocytes are not believed to be proliferative outside of conditions of glial 
scar formation, which is a specific, irreversible form of astrocyte reactivity. Reactive astrocytes 
contribute to the production and release of cytokines and the neuroinflammatory process during 
injury and neurodegeneration. Reactive astrocytes should not be confused with activated 
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astrocytes, as the latter pertains to astrocyte responses to neurotransmission (Ben Haim et al., 
2015). 
 Astrocytes can also be considered the master regulators of brain metabolism. In this 
thesis chapter, the importance of astrocytes’ metabolism in the regulation of neurotransmitter 
recycling and synthesis, central carbon metabolism and bioenergetics, as well as redox 
homeostasis and antioxidant/xenobiotic defense is discussed. Our goal is to highlight the 
metabolic niche astrocytes fill within overall brain metabolism. 
3.2 Astrocytes’ metabolism and bioenergetics: a glycolytic cell 
 While the mass of the human brain accounts for approximately 2% of total body weight, 
its oxidative metabolism accounts for ~20% of the body’s total oxidative metabolism (Rolfe and 
Brown, 1997;Attwell and Laughlin, 2001). Most of this oxidative energy (estimated 75-80%) is 
utilized at the synapse to maintain and restore ionic gradients, and for the uptake and recycling of 
neurotransmitters (Riveros et al., 1986;Wong-Riley, 1989;Attwell and Laughlin, 2001;Hyder et 
al., 2013) (Figure 3.3.4). By comparison, the metabolic processes in astrocytes have been 
estimated to account for between 5% and 15% of the total ATP expenditure in the brain (Attwell 
and Laughlin, 2001;Belanger et al., 2011). Glucose is the primary energy substrate in the adult 
brain, however alternate energy sources can fuel brain function. Lactate transport across the 
blood-brain barrier (BBB) (Figure 3.3.1) provides ~8%–10% of the brain’s energy requirements 
under basal conditions (Boumezbeur et al., 2010), and it has been estimated to supply ~20%–25% 
of energy during energy demanding activities (van Hall et al., 2009). As plasma lactate 
concentrations rise, lactate uptake in the CNS increases coinciding with a decrease in  
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Figure 3.1: Central Carbon Metabolism in Astrocytes 
(1.1) In astrocytes, glucose is used via glycolysis as a principal energy source. The PPP creates redox 
potential by replenishing the NADPH pool. Glucose storage in glycogen is restricted or transient at most. 
Glucose carbons can also be used for cysteine (Cys) (trans-sulfuration, not shown) and glycine (Gly) 
synthesis.  
(1.2) Pyruvate is the principal end product of glycolysis in astrocytes. Astrocytes convert most pyruvate 
into lactate by LDH5 to be export to the extracellular space. Pyruvate also enters the mitochondria (see 
Figure 2 for details). 
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(Figure 3.1: Central Carbon Metabolism in Astrocytes continued) 
 (1.3) FAs are sorted by their size: 12 or less carbons can directly enter the mitochondria, 13-22 carbons 
pass into the mitochondria through a shuttle (see Figure 2 for details), and 23+ carbons enter peroxisomes 
to create shorter FA products through /β-oxidation. The esterification of FAs (ACS) limits their ability to 
pass through membranes, and is required for FAO. 
 (1.4) Peroxisomal /β-oxidation occurs in a similar manner to mitochondrial FAO but, without an ETC, 
FADH2 donates its electrons directly to oxygen to create H2O2 that is neutralized by CAT. The fate of 
NADH in peroxisomes has yet to be determined. Multiple species of FA transport systems exist within 
peroxisomes, each with different affinities for various FA lengths. Exported FAs enter the mitochondria to 
complete FAO. 
(1.5) Ketone bodies in astrocytes can enter as substrates for mitochondrial metabolism (see Figure 2 for 
details) or can be the end product in mitochondrial metabolism that astrocytes export for other cells.  
(1.6) Astrocytes utilize glutamate (Glu) for glutamine (Gln) synthesis (Glu-Gln cycle), Cys acquisition 
(xCT or EAAT3), and for GSH synthesis, this later exported via (MRP1). In astrocytes, Glu is imported 
from the synaptic cleft by EAAT1/2 or derived from transamination of the mitochondrial TCA intermediate 
KG by Asp amino transferases (GOT1/2). Glu can also be used to power the malate (Mal)-Asp shuttle 
through AGC or Aralar 1, or enter the mitochondria as a substrate for oxidative phosphorylation (see Figure 
2 for details).  
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glucose uptake (Smith et al., 2003;van Hall et al., 2009). When required, an important pool of 
lactate is always available as the extracellular levels of lactate (0.5-1.5 mM) are similar to those 
of glucose (Magistretti and Allaman, 2015).  
 Metabolism in astrocytes and neurons is interconnected, and it has been clearly 
demonstrated that neurons depend upon astrocytes for a variety of metabolic processes. The in 
vivo energy demands of astrocytes can be fulfilled in the absence of oxidative phosphorylation, 
with an observed increase in lactate production in mutants of Cox10 (part of the cytochrome c 
oxidase complex and required for complex IV function), indicating that astrocytes are glycolytic  
(Figure 3.1.1 and 3.3.2) (Supplie et al., 2017). Glucose has been reported as being the 
preferential energy substrate of astrocytes over lactate, though glucose uptake does not match 
theoretical bioenergetic output (Bouzier-Sore et al., 2006;Jakoby et al., 2014). Pyruvate entry into 
the tricarboxylic acid (TCA or Krebs) cycle (Figure 3.2.1) is limited by a reduced activity of 
pyruvate dehydrogenase (PDH) in astrocytes due to phosphorylation (Bouzier-Sore et al., 
2006;Halim et al., 2010;Jakoby et al., 2014) creating a surplus of pyruvate due to the high levels 
of glucose consumption (Figure 3.1.2). In contrast to astrocytes, glycolysis in neurons is 
restricted by the continuous degradation of 6-phosphofructo-2-kinase/fructose-2, 6-
bisphosphatase-3 (PFKFB3), which catalyzes the synthesis of fructose-2,6-bisphosphate 
(F2,6BP) an allosteric activator of phosphofructokinase 1 (PFK1) (Almeida et al., 2004;Herrero-
Mendez et al., 2009). Accordingly, glucose utilization in neurons is directed to the pentose 
phosphate pathway (PPP) in order to regenerate nicotinamide adenine dinucleotide phosphate 
(NADPH) for the reductive recycling for GSH upon oxidative stress (Figure 3.3.3) (Delgado-
Esteban et al., 2000;Vaughn and Deshmukh, 2008;Herrero-Mendez et al., 2009;Bolanos, 2016). 
The astrocyte-neuron lactate shuttle (ANLS) hypothesis states that a large portion of glucose 
metabolism in astrocytes is directed to lactate production and this is subsequently shuttled to 
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neurons as fuel for oxidative phosphorylation (OXPHOS) (Figure 3.3.2 and 3.3.3) (Pellerin and 
Magistretti, 1994;Magistretti and Allaman, 2015;Machler et al., 2016). However, recent studies 
also demonstrate that during energy-demanding conditions neurons have the capacity to 
upregulate glucose metabolism, and have been used to argue against the ANLS hypothesis  
(Figure 3.3.3) (Patel et al., 2014;Lundgaard et al., 2015;Diaz-Garcia et al., 2017). 
 Astrocytes also store energy in the form of glycogen, which can be broken down to 
lactate. Yet due to the limited amount of glycogen stored in astrocytes (∼3 to 12 μmol glycogen 
per g of tissue, 1-6% of total glucose (Choi et al., 1999)), its contribution to the maintenance of 
either neuronal or astrocyte energy-dependent processes under stress conditions is still unclear 
(Bak et al., 2018). There is strong evidence supporting a robust oxidative metabolic capacity in 
astrocytes (1/3 of total brain glucose oxidative metabolism and 1/2 of total brain lactate oxidative 
metabolism) (Zielke et al., 2009), and even higher transcriptional levels of both glycolytic and 
TCA cycle enzymes in astrocytes vs neurons, as well as a high concentration of mitochondria in 
astrocyte endfeet (Figure 3.3.6) (Lovatt et al., 2007). Nevertheless, astrocytes deficient in 
mitochondrial respiration survive as glycolytic cells, both in vitro and in vivo (Supplie et al., 
2017). What then is the physiological importance of mitochondrial metabolism in astrocytes? We 
next discuss the particularities of mitochondrial metabolism in these glial cells and its importance 
for neurotransmission and redox balance. 
3.3 Mitochondrial metabolism in astrocytes: Anaplerosis and Cataplerosis 
 Oxidative metabolism in mitochondria is primarily fueled by pyruvate, fatty acids/ketone 
bodies, and glutamine/glutamate. Pyruvate generated from glycolysis is actively transported into 
the mitochondrial matrix via the mitochondrial pyruvate carrier (MPC1) to be subsequently 
decarboxylated and combined with coenzyme A (CoA) (Figure 3.2.1). Oxidative decarboxylation 
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of pyruvate to acetyl-CoA is mediated by PDH and is coupled with the reduction of NAD
+
 to 
NADH. Subsequently, citrate synthase catalyzes the condensation of oxaloacetate with acetyl-
CoA to generate citrate. Pyruvate decarboxylation is the primary carbon source for the TCA cycle 
and is sufficient to sustain oxidative carbon flux during energy consumption, as the last step in 
the cycle regenerates oxaloacetate to be combined further with another acetyl-CoA molecule 
generated by PDH (a closed loop) (Figure 3.2.1). However, TCA cycle intermediates also 
provide precursors for the biosynthesis of several classes of molecules. TCA intermediates leave 
the cycle via cataplerotic reactions linked to biosynthetic processes, while anaplerotic reactions 
supplement carbons back into to the TCA cycle. A balance between anaplerosis and cataplerosis 
controls the entry and exit of carbons into the TCA cycle, and is essential for biosynthetic 
processes  (Figure 3.2.1) (Owen et al., 2002).  
 Pyruvate carboxylase (PC) is a major anaplerotic enzyme in the mitochondria that 
generates oxaloacetate from pyruvate in an ATP-dependent manner (Figure 3.2.1), replenishing 
carbons lost by the export of oxaloacetate, citrate, and -ketoglutarate (KG) from the TCA 
cycle, for gluconeogenesis, fatty acid (FA) synthesis, and amino acid synthesis, respectively 
(Figure 3.1.2, 3.1.6 and 3.2.6). In astrocyte gluconeogenesis, oxaloacetate is converted to 
phosphoenolpyruvate (PEP) in the  mitochondria by phosphoenolpyruvate carboxykinase 
(PEPCK2), as cytosolic phosphoenolpyruvate carboxykinase (PEPCK1) activity has not been 
detected in the astrocyte cytosolic fractions (Schmoll et al., 1995). While PEP has been shown to 
exit mitochondria (Garber and Ballard, 1969;Stark et al., 2009), the precise mechanism has not 
been determined, with the citrate isocitrate carrier (CIC) and adenine nucleotide transporter 
(ANT) being proposed (Stark and Kibbey, 2014). In the brain, it has been long recognized that 
PC is primarily expressed in astrocytes and to a lesser extent in microglia, oligodendrocytes and 
ependymal cells (Shank et al., 1985;Murin et al., 2009). However, as mentioned above, PDH  
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Figure 3.2: Mitochondrial Metabolism in Astrocytes 
(2.1) The astrocyte TCA cycle is principally used for biosynthetic processes, not OXPHOS. Synthesis of 
Ac-CoA from pyruvate is limited by the phosphorylation of PDH (P) Cataplerotic reactions of the TCA 
cycle are matched by anaplerotic carbon inputs. Anaplerotic inputs in astrocyte include pyruvate 
carboxylatyion to OAA, acetyl-CoA (Ac-CoA) and succinyl-CoA (succ-CoA) synthesis from FAO, and 
ketolysis Ac-CoA and glutamate, and GABA neurotransmitter synthesis from KG and succinate, 
respectively. Astrocyte cataplerotic outputs include KG, malate, and citrate. 
(2.2) FAO produces Ac-CoA and propionyl-CoA (Prop-CoA) that are directed to either ketogenesis, 
ketolysis, or as anaplerotic input to the TCA cycle. FAO generates a high yield of NADH and FADH2 (see 
2.5).  
38 
 
(Figure 3.2: Mitochondrial Metabolism in Astrocytes continued)  
(2.3) Ketogenesis condenses Ac-CoA to either acetoacetate (AcAc) or β-hydroxybutyrate (ßHB). FAO is 
the principal source of ketogenesis in astrocytes. Ketolysis reverses this process, requiring succ-CoA from 
either prop-CoA (FAO or BCAA metabolism [not shown]), or the TCA cycle as a driving force. 
(2.4) Mitochondrial Glu synthesis and incorporation into the TCA cycle in astrocytes is performed by 
transamination (GOT2, ALAT, BCAT) or by deamination (GDH, GLS, GABA-T) of KG allowing 
glutamate to act in both cataplerosis and anaplerosis.  
(2.5) The astrocyte ETC is not required for survival, and its activity has been reported to be a source of 
ROS due to inefficient complex activity and electron transfer. Importantly high yield of NADH and FADH2 
generated from FAO (see 2.2) can increase ROS formation due to the transfer of electrons from FADH2 to 
ETF, creating a backpressure of electrons flowing from complex I. 
(2.6) While the outer mitochondrial membrane is fairly permeable, numerous transporters exist on the inner 
membrane to facilitate entry and exit of a number of metabolites from the mitochondrial matrix.  
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activity in astrocytes is reduced by its phosphorylation and thus an additional carbon source is 
proposed to exist to supplement acetyl-CoA to the TCA cycle (Figure 3.2.1) (Halim et al., 2010). 
FA oxidation (FAO) has been proposed to be the preferable substrate for acetyl-CoA synthesis in 
astrocytes (Figure 3.1.4 and 3.2.2), but the physiological implications are still unclear (Halim et 
al., 2010;Adina-Zada et al., 2012;Panov et al., 2014). 
3.4 FA oxidation (FAO) in astrocytes: The “missing link” 
 Ketone bodies are water-soluble molecules derived from FA metabolism in the liver, 
supplying energy to peripheral tissues including the brain. Ketone bodies have been shown to be 
produced by astrocytes as well (Blazquez et al., 1998;Cullingford et al., 1998;Guzman and 
Blazquez, 2001;Thevenet et al., 2016). During starvation up to ~ 70% of the brain’s energy can 
be supplied by ketone bodies (Owen et al., 1967). Ketone bodies are produced in the 
mitochondria from acetyl-CoA in three sequential steps mediated by: 1) acetyl-CoA 
acetyltransferase 1 (ACAT1) also known as acetoacetyl-CoA thiolase or thiolase II (acetyl-CoA 
→ acetoacetyl-CoA, a reversible reaction); 2) β-hydroxy-β-methyl glutaryl (HMG)-CoA synthase 
(HMCS1, acetoacetyl-CoA → HMG-CoA); and 3) HMG-CoA lyase (HMGCL, HMG-CoA → 
Acetoacetate). Acetoacetate (AcAc) is then decarboxylated to acetone or metabolized to β-
hydroxybutyrate (βHB) via β-hydroxybutyrate dehydrogenase (BDH) (Figure 3.2.3). Ketone 
bodies can cross the BBB and plasma membranes via monocarboxylate transporters (MCT1, 2, 4) 
(Figure 3.1.5, 3.3.1 and 3.3.4) (Halestrap and Price, 1999;Morris, 2005). At high concentrations, 
ketone bodies have been proposed to support basal and activity-dependent needs of neurons and 
glutamatergic signaling, while decreasing glucose utilization (Lopes-Cardozo et al., 
1986;Kunnecke et al., 1993;Sibson et al., 1998;Magistretti et al., 1999;Chowdhury et al., 
2014;Courchesne-Loyer et al., 2017). Within the cell, ketone body transport across the 
40 
 
mitochondrial membrane has not been fully characterized. While the mitochondrial pyruvate 
carrier (MPC1) has been implicated in ketone body transport, inhibition of the MPC1 does not 
abolish ketone body accumulation in the mitochondria, indicating that an undetermined 
transporter system or diffusion is present  (Figure 3.2.6) (Paradies and Papa, 1977;Halestrap, 
1978;Booth and Clark, 1981;Achanta and Rae, 2017). In mitochondria, ketolysis starts when 
BDH converts β-hydroxybutyrate back to acetoacetate, which is activated to acetoacetyl-CoA by 
succinyl‐CoA‐3-oxoacid-CoA transferase (SCOT). Acetoacetyl-CoA is then degraded by ACAT1 
generating acetyl-CoA that can be incorporated into the TCA cycle (Figure 3.2.3). Neurons, 
astrocytes and oligodendroglia have been shown to be fully capable of using ketone bodies as 
metabolic fuel in vitro (Chechik et al., 1987). 
 In addition to ketone bodies, FAs are also energy substrates for the brain, and unlike 
ketone bodies, they diffuse across the BBB rather than relying on transport systems for their 
influx.  The main source of FAs crossing into the brain are non-esterified long-chain FAs 
complexed with albumin and circulating lipoproteins (Hamilton and Brunaldi, 2007). Transport 
of non-esterified FAs across the BBB is mediated by passive diffusion (FA flip-flop) or by FA 
transporters including FA transport proteins (FATP1 and 4, with intrinsic Acyl-CoA synthetase 
activity) and the FA translocase (FAT/CD36) (Figure 3.3.1) (Gnaedinger et al., 1988;Purdon et 
al., 1997;Hamilton and Brunaldi, 2007;Ouellet et al., 2009;Mitchell et al., 2011). The exact 
transport mechanisms that mediate the uptake of FAs into neurons or astrocytes are still unclear. 
A recent report suggests that FATP1 and 4 mediate FA uptake in glial cells. Importantly, while 
neurons are capable of synthesizing significant amounts of lipids during bioenergetic excess, they 
are reported to be dependent on an apolipoprotein E (ApoE) shuttle system to transfer them to 
astrocytes to avoid neurodegenerative phenotypes  (Figure 3.3.6) (Liu et al., 2015;Liu et al., 
2017). To utilize FAs metabolically (FAO), FAs must be esterified to CoA in an ATP-dependent 
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process by acyl-CoA synthetases (ACS), a process that is often linked to, or performed shortly 
after, FA transport by FATPs  (Figure 3.1.3) (Mashek et al., 2007;Anderson and Stahl, 2013). In 
the brain, signaling through peroxisome proliferation activated receptor beta (PPARß, 
predominantly expressed in neurons but also glia) increases the expression of ACS2 (Basu-
Modak et al., 1999), in turn increasing the oxidation of exogenously supplied FAs in neurons 
(Marszalek et al., 2004). Astrocytes have an increased expression of both PPARα and ACS1 
compared to neurons (Basu-Modak et al., 1999), which has been linked to the upregulation of 
genes involved in FAO and ketogenic processes  (Cullingford et al., 2002). Carnitine 
palmitoyltransferase 1a (CPT1a) transfers the acyl groups from esterified FAs (acyl-CoA) to L-
carnitine, producing acylcarnitine esters which are transported across the outer and inner 
mitochondrial membranes via the voltage-dependent anion channel (VDAC) and the 
carnitine/acylcarnitine translocase (CACT) transport, respectively. Then, CPT2 converts 
acylcarnitine back to acyl-CoA in the mitochondrial matrix (Figure 3.3.4) (Houten and Wanders, 
2010;Panov et al., 2014;Romano et al., 2017).  
 In the mitochondria, acyl-CoAs are principally broken down into acetyl-CoA by β-
oxidation in a series of sequential reactions that include: 1) an initial FAD-dependent 
dehydrogenation of acyl-CoAs by acyl-CoA dehydrogenase (ACD) that generates FADH2; 2) a 
subsequent hydration step mediated by enoyl-CoA hydratase (ECH)  forming 3-
hydroxy(OH)acyl-CoA; 3) generation of 3-ketoacyl-CoA via 3-OHacyl-CoA dehydrogenase 
(HAD)  in an NAD+-dependent manner regenerating NADH; and finally 4) cleavage and release 
of acetyl-CoA via thiolase I leaving an acyl-CoA two carbon atoms shorter that re-enters the 
pathway. The last three steps are carried by a heteroctamer protein complex called the 
mitochondrial trifunctional protein (Figure 3.2.2) (Houten and Wanders, 2010;Panov et al., 
2014;Romano et al., 2017). For FAs/acyl-CoAs with odd numbered carbons, β-oxidation will 
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yield propionyl-CoA rather than acetyl-CoA from the final carbons of the acyl-CoA. Propionyl-
CoA is converted to succinyl-CoA in an ATP-dependent manner by a series of mitochondrial 
enzymes, providing an anaplerotic input to the TCA cycle and acting as a co-substrate in the 
ketolytic conversion of acetoacetyl-CoA to acetoacetate by SCOT (Figure 3.2.3). In the event 
that the β-carbon of a FA is methylated, -oxidation occurs to remove one carbon unit as formic 
acid (formic acid is converted to carbon dioxide (CO2)), shifting the methylated carbon from the β 
to  position, allowing β-oxidation to resume. The steps in -oxidation include: 1) hydroxylation 
of the -carbon by phytanoyl-CoA hydroxylase (PhyH/Pahx) utilizing the conversion of KG to 
succinate as a driving force; 2) decarboxylation by 2-hydroxyphytanoyl-CoA lyase (2-HPCL) 
releasing formyl-CoA and a fatty aldehyde; 3) oxidation of the fatty aldehyde by aldehyde 
dehydrogenase generating NADH and an acyl-CoA one carbon shorter than the original product 
(Jansen and Wanders, 2006). 
 A large quantity of ATP can be generated from FAO (one molecule of palmitic acid 
provides approximately 115 ATPs vs 32 ATPs generated from glucose oxidation). Despite its 
high-energy potential, FAs have long been considered a poor energy substrate in the brain. The 
brain as a whole was thought to be limited in β-oxidation capacity as thiolase I, ACD and ECH 
activities are 0.7%, 50% and 19% that of the heart mitochondria (Yang et al., 1987), though it 
must be noted that glial and neuronal forms of the enzymes were not assayed independently 
(Figure 3.2.2). While there are three known carnitine palmitoyltransferase 1 (CPT1) isoforms, 
CPT1a has a low expression in the whole brain and is not expressed in neurons (Jernberg et al., 
2017), CTP1b is not expressed in the brain (Obici et al., 2003;Lavrentyev et al., 2004), and 
CPT1c localizes exclusively to the endoplasmic reticulum in neurons and has not been shown to 
participate in FAO (Wolfgang et al., 2006;Sierra et al., 2008) but has been implicated in ROS 
management (Lee and Wolfgang, 2012). Lower CPT1a expression and activity restricts 
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mitochondrial oxidation of FAs (Bird et al., 1985), except for those with 12 or fewer carbons, 
which can passively diffuse across the mitochondrial inner membrane (Figure 3.1.3, 3.2.2). Yet 
the brain has been demonstrated to metabolize carbons from FAs in vivo, accounting for ~20% of 
the total acetyl-CoA pool when labeled octanoate is supplied to the bloodstream (Ebert et al., 
2003).This is believed to occur predominantly in astrocytes, based on comparisons of astrocytes, 
oligodendrocytes and neurons in primary cultures (Edmond et al., 1987).  
 Astrocytes have a high buffering capacity against ROS compared to neurons (Sun et al., 
2006), and FAO is proposed to induce higher amounts of ROS formation. One cycle of β-
oxidation generates one molecule of FADH2 and NADH, increasing the total FADH2/NADH ratio 
per acetyl-CoA created compared to glycolysis (Figure 3.2.2). When ACD transfers electrons 
from acyl-CoA to FAD, it is coupled to the subsequent transfer of electrons from the resultant 
FADH2 to the electron transferring flavoprotein (ETF). The follow-up transfer of electrons from 
ETF to ubiquinone by ETF dehydrogenase creates a backpressure of electrons flowing through 
complex I (donated from NADH) and complex II (donated from succinate) to ubiquinone that 
enhances the probability of leakage and formation of ROS (Figure 3.2.5). Thus, it has been 
proposed that restricting FAO protects neurons against oxidative damage beyond the stages of 
development (Schonfeld and Reiser, 2013;2017). In the brain, inhibition of FAO by methyl 
palmoxirate has been shown to reduce the concentrations of non-enzymatically oxidized 
metabolites derived from poly-unsaturated fatty acid (PUFA), indicating that ROS are being 
generated from FAO (Chen et al., 2014).  
 However, mechanism of ROS generation from FA substrates is not universal, and 
depends upon the length and structure of the FA. Very long chain FAs (VLCFAs) that are not 
esterified have been shown to integrate into artificial phospholipid bilayers, desorpting at slower 
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rates than shorter fatty acids and disrupting membrane fluidity (Ho et al., 1995). This integration 
and disruption by VLCFAs has been shown to occur in the inner mitochondrial membrane, 
decreasing the membrane potential by protonophoric activity, and reducing ROS generated from 
reverse electron transport (RET) (Hein et al., 2008). The protonophoric property, and its resulting 
decrease in ROS from hyperpolarization, has been demonstrated in medium chain FAs 
(MCFAs)(Korshunov et al., 1998), long chain FAs (LCFAs), and branched chain FAs (Schonfeld 
and Wojtczak, 2007). This protonophoric capacity of FAs decreases as the length of the FA 
decreases (Schonfeld and Wojtczak, 2016), while branched FAs such as phytanic acid show an 
increased protonophoric activity compared to their straight chain FA counterparts (Komen et al., 
2007;Schonfeld and Reiser, 2016). Additionally, application of carnitine esters as substrates 
demonstrated that RET was not occurring in the mitochondria, furthering that RET is not a 
prominent form of ROS production during FAO (Schonfeld et al., 2010). 
 While protonophoric properties of FAs can mitigate the effects of hyperpolarization/RET, 
FAs can promote ROS generated through forward electron transport and by interfering with 
electron transport. Isolated mitochondria increased ROS production proportionally to FA 
exposure in the presence of the recoupling agent carboxyatractyloside (Schonfeld and Wojtczak, 
2007) and during uncoupling with CCCP (Cocco et al., 1999), indicating that ROS was being 
generated independently of the protonophoric effects. Interestingly, branched phytanic acid and 
poly unsaturated arachidonic acid demonstrated stronger ROS effects than unbranched saturated 
FAs in the aforementioned studies (Cocco et al., 1999;Schonfeld and Wojtczak, 2007). 
Mitochondria exposed to low concentrations of palmitoylcarnitine were also found to generate 
ROS while maintaining membrane potential, with rotenone (complex I inhibition) having 
minimal effect on ROS while antimycin (complex III inhibition) dramatically increased ROS 
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(Seifert et al., 2010). As described in (Schonfeld and Wojtczak, 2008), despite the evidence of 
electron transfer interference by FAs, the mechanism is not well understood. 
 In the brain, FAO occurs primarily in astrocytes (Edmond et al., 1987;Auestad et al., 
1991;Schonfeld and Reiser, 2013). While both astrocytes and oligodendrocytes uptake saturated 
and unsaturated FAs (Hofmann et al., 2017), CTP1a seems to be found primarily in astrocytes 
and neural progenitor cells, while absent in neurons, microglia, and oligodendrocytes (Jernberg et 
al., 2017). As such, carnitine deficiency causes a metabolic encephalopathy that is characterized 
by astrocytic swelling and mitochondrial expansion, corroborating that FAO is an essential 
metabolic component of astrocytic function (Kimura and Amemiya, 1990;Calabrese et al., 
2005;Jones et al., 2010). CPT1a activity is negatively regulated by malonyl-CoA, a molecule 
synthesized by acetyl-CoA carboxylase (ACC) from cytosolic acetyl-CoA. Malonyl-CoA is also a 
principal component of fatty acid synthesis, making this molecule the regulator of FAO and 
lipogenesis (Foster, 2012). ACC is inhibited by phosphorylation via the energy sensor adenosine 
monophosphate (AMP)-activated protein kinase (AMPK), which links energy deficiency with 
mitochondrial β-oxidation (Figure 3.3.4). Recurrent low glucose exposure has been shown to 
activate AMPK and increase FAO dependency in astrocytes (Weightman Potter et al., 2019). In 
another study, astrocyte activation with ciliary neurotrophic factor (CNTF) was also shown to 
activate AMPK and increases β-oxidation and ketolysis (Escartin et al., 2007). In contrast, upon 
hypoxic conditions or high concentrations of FAs, ketogenesis is induced in astrocytes and this is 
regulated as well by AMPK signaling (Blazquez et al., 1999;Takahashi et al., 2014). 
 Peroxisomes are located throughout the brain but are primarily found in astrocytes and 
oligodendrocytes (Troffer-Charlier et al., 1998). FAs with more than 22 carbons cannot be 
transported into the mitochondria via the carnitine shuttle and thus, are broken down first by 
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peroxisomes. As in mitochondria, fatty acids must be esterified to CoA before undergoing FAO 
in peroxisomes. (Figure 3.1.4 and 3.3.4). Because peroxisomes lack an ETC, electrons from 
FADH2 are transferred directly to O2 creating H2O2 that is scavenged by catalase (CAT). Within 
the peroxisome, FAs are shortened to acetyl-CoA, propionyl-CoA, and a wide range of long, 
medium, and short chain FAs (LCFAs/MCFAs/SCFAs) of 22 carbons or less. A variety of export 
systems exist within the peroxisomes, each with different affinities for different lengths of FAs, 
including carnitine-transferases (carnitine acetyltransferases (CRATs), carnitine 
octanoyltransferases (CROTs)), and thiolases (acyl-CoA thioesterases (ACOTs)) transport 
systems (Figure 3.1.4) (Antonenkov and Hiltunen, 2012). Additionally, peroxisomes have been 
shown to possess ketogenic enzymes, implicating peroxisomes as another potential source of 
ketone bodies and cholesterol (Hovik et al., 1991;Antonenkov et al., 2000;Olivier et al., 2000). 
Dysfunction of peroxisomal processes has been linked to demyelination, oxidative stress, 
inflammation, cell death, and abnormalities in neuronal migration and differentiation (Trompier 
et al., 2014). Defects in the ATP binding cassette subfamily D member 1 (ABCD1) transporter 
that translocates very LCFAs into peroxisomes (Figure 3.1.4), leads to the accumulation of these 
fats in cells and tissues. VLCFAs and branched chain FAs can interfere directly with the ETC by 
opening the permeability transition pore, disrupting calcium balance and depolarizing the 
mitochondria (Hein et al., 2008;Kruska et al., 2015;Schonfeld and Reiser, 2016). LCFAs (13 to 
21 carbons) activate peroxisome proliferator-activated receptors, transcription factors that 
stimulate both β-oxidation and ketogenesis as well as mitochondrial and peroxisome biogenesis. 
Recent reports have also demonstrated that peroxisome biogenesis requires the generation of pre-
peroxisomes from mitochondrial derived vesicles (Sugiura et al., 2017). 
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3.5 Mitochondrial Metabolism in Astrocytes and Neurotransmitter Homeostasis 
 Astrocyte processes extending to synaptic clefts play an important role in regulating 
synaptic transmission, particularly glutamatergic signaling. After its vesicle-mediated release, the 
excitatory neurotransmitter glutamate is taken from the synaptic cleft by astrocytes in a Na
+
 
dependent manner via the excitatory amino acid transporters EAAT1 (glutamate aspartate 
transporter, GLAST) or EAAT2 (glutamate transporter 1, GLT-1) (Figure 3.3.4). In the cytosol, 
glutamate is then converted into non-excitatory glutamine via glutamine synthetase (GS), and 
transferred back to neurons via the Na
+
-coupled neutral amino acid transporters (SNATs) to be 
converted back into glutamate in neurons via phosphate-activated glutaminase (PAG) (Figure 
3.3.4) (Norenberg and Martinez-Hernandez, 1979;Anderson and Swanson, 2000;Schousboe et al., 
2013;Leke and Schousboe, 2016). In astrocytes, despite the presence of a weak mitochondrial 
targeting sequence, GS is localized in the cytosol because the mitochondrial membrane potential 
is not negative enough to drive GS into the mitochondria (Figure 3.1.6 and 3.3.2) (Matthews et 
al., 2010). Neurons lack PC activity (Yu et al., 1983), restricting their ability to replenish TCA 
intermediates lost during neurotransmitter release (anaplerotic reaction). Thus, the glutamate-
glutamine cycle between neurons and astrocytes, not only terminates/modulates glutamatergic 
signaling, preventing excitotoxicity triggered by excessive or prolonged exposure to glutamate, 
but it also replenishes the neurotransmitter pool in neurons (Belanger et al., 2011) (Figure 3.3.4).  
 Not all the glutamate taken from the synaptic cleft by astrocytes becomes glutamine. 
There is evidence that a significant portion is incorporated into the TCA cycle via oxidative 
metabolism (Figure 3.2.4). Glutamate transport into the mitochondria is mediated via the 
aspartate/glutamate carrier antiporter (AGC or Aralar 1) or via the glutamate carrier (GC1 or 
SLC25A22), a symporter for glutamate and protons (H
+
). Controversy still exists about the  
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Figure 3.3: Neuronal-Astrocytic Metabolic Cooperation 
(3.1) GLUTs (glucose), MCTs (Lactate and ketone bodies), and FATPs (fatty acids) transporters facilitate 
the transport of carbon sources across the BBB. 
(3.2) Astrocytes utilize glucose for the production of ATP (glycolysis), regeneration of NADPH (PPP), and 
to feed mitochondrial biosynthetic processes. Astrocytes synthesize and export GSH (MRP1), lactate 
(MCT1/4), ketone bodies (MCT1/2), and Gln (at glutamatergic SNAT5 or GABAergic SNAT3 synapses) 
that can be utilized by neurons for energy production and synthesis of neurotransmitters.  
(3.3) Neurons utilize glucose primarily for the regeneration of NADPH (PPP), with some studies 
suggesting that glycolysis can be upregulated during energy-demanding conditions. Lactate and ketone 
bodies are used in ATP production (OXPHOS). Neurons import GSH precursors from  
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(Figure 3.3: Neuronal-Astrocytic Metabolic Cooperation continued) 
astrocytes via EAATs and GlyT1, lactate and ketone bodies via MCT1/2, and Gln through SNAT2/7 
(SNAT1/7 in GABAergic neurons).  
(3.4) Upon their release into the synaptic cleft Glu and GABA neurotransmitters can be uptaken into 
neurons via EAATs and the GABA transporter 1 (GAT1). However, astrocytes have a higher capacity to 
uptake and metabolize these neurotransmitters. In astrocytes, GABA is metabolized in the mitochondria 
(see Figure 2.4). Glu is taken in by astrocytes (EAAT1/2), converted to Gln (GS), and exported (SNAT5) 
for neuronal uptake (SNAT7). In the neurons, Gln is converted to Glu via PAG and then Glu can be 
converted to GABA via glutamate decarboxylase (GAD). Neurotransmitters are subsequently loaded into 
vesicles via vesicular transporters (VGLUT or VGAT), which do not require ATP per se, but their activity 
is coupled to that of the vacuolar H
+
 ATPase. Na
+
/K
+
 ATPases maintain the electrochemical gradient 
required to maintain neuronal excitability (not shown) and in astrocytes, essential to drive neurotransmitter 
uptake.  
(3.5) During periods of excess Ac-CoA lipid synthesis is initiated and transferred into lipid droplets. Lipids 
are then transported to astrocytes in an apolipoprotein D/E dependent manner, and taken in by fatty acid 
transporter proteins 1 and 4 (FATP1 and 4). 
(3.6) In astrocytes, mitochondria co-localize on the plasma membrane with EAAT1/2, Na
+
/K
+
 ATPases, 
and glycolytic enzymes.  
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Figure 3.4: Fatty Acid Transport into the Mitochondria 
(4.1) Coenzyme A thioesters (Acyl-CoAs) cannot cross mitochondrial membranes. CPT1a facilitates the 
transfer of the acyl group from CoA to carnitine. Acyl-carnitines are permeable to the outer mitochondrial 
membrane, but not the inner mitochondrial membrane, requiring the transport via carnitine-acylcarnitine 
translocase (CACT) to reach the mitochondrial matrix. Once in the matrix, CPT2 converts the acyl-
carnitine back to an acyl-CoA, which can then undergo FAO (see Figure 2.2). The released carnitine is then 
transported back across the inner mitochondrial membrane by CACT to be reused in the cytosol. 
(4.2) Non-esterified fatty acids (NEFAs) of 12 or less carbons do not require the carnitine shuttle system, 
and can diffuse across both mitochondrial membranes. However, they still require esterification to CoA by 
mitochondrial ACS before they can be metabolized by FAO. 
(4.3) The carnitine shuttle system is regulated by malonyl-CoA, a precursor to fatty acid synthesis which 
also inhibits CPT1a activity. Malonyl-CoA is principally produced from citrate that is broken into OAA 
and acetyl-CoA in the cytosol by ATP citrate lyase (ACL). The released acetyl-CoA is carboxylated by 
acetyl-CoA carboxylase (ACC) to malonyl-CoA. ACC is modulated by AMPK activity, phosphorylating 
ACC and reducing ACC activity. 
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contribution of AGC to the uptake of glutamate in astrocytic mitochondria, as it has been shown 
to be primarily expressed in neurons. However, while the AGC activity in astrocytes corresponds 
only to 7% of the total brain AGC activity, it is calculated to be twice the minimum required for 
glutamate production and degradation (Figure 3.2.6) (Hertz, 2011). AGC is also central to the 
malate-aspartate shuttle (Figure 3.1.6), a system that allows the transfer of NADH electrons 
generated in the cytosol,  from processes such as glycolysis, to the mitochondria (Amoedo et al., 
2016). On the other hand, knockdown of GC1 suggests that this carrier is the main gate for net 
glutamate entry into mitochondria for oxidative metabolism in astrocytes (Figure 3.2.6) (Goubert 
et al., 2017).  In the mitochondria, glutamate is metabolized to KG by transamination via 
aspartate aminotransferase (GOT2), and to a lesser extent by alanine (ALAT) and branched chain 
aminotransferases (BCAT) (Figure 3.2.4). In addition, -KG can also be synthesized from 
glutamate via glutamate dehydrogenase (GDH), which is also a source of NADPH. While 
glutamate transamination via GOT2 generates a truncated TCA cycle due to the requirement of 
oxaloacetate as a co-substrate, GDH-mediated dehydrogenation can serve as an anaplerotic 
reaction to replenish TCA intermediates (Figure 3.2.1 and 3.2.4) (Sonnewald et al., 1993;Olsen 
and Sonnewald, 2015;McKenna et al., 2016). Astrocytes deficient in GDH increase their reliance 
on GOT2 and their glycolytic input to PC, which is paralleled by an accumulation of intracellular 
glutamate, underlying the importance of GDH in anaplerosis (Nissen et al., 2015;Pajecka et al., 
2015). It should be noted that humans, unlike most other animals including mice and rats, have an 
additional GDH2 isoform that is expressed solely in astrocytes. Expression of GDH2 in rat 
cortical astrocytes increased glutamate uptake and metabolism, reducing their dependence on 
glucose and increasing their capacity to utilize branched chain amino acids (BCAA) (Nissen et 
al., 2017). Importantly, glutamate to glutamine metabolism is not determined by the extracellular 
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glutamate concentration. However, the entry of glutamate into the TCA cycle seems to be 
triggered by high extracellular glutamate concentrations (high µM) (McKenna et al., 1996). 
 The homeostasis of the inhibitory neurotransmitter -aminobutyric acid (GABA) is 
similarly linked to the glutamate-glutamine cycle. GABA is synthesized in neurons from the 
decarboxylation of glutamate by glutamate decarboxylase (GAD). After its vesicular release, 
GABA is uptaken by astrocytes through the GABA transporter (GAT3) (Figure 3.3.4). GABA is 
then metabolized by GABA transaminase (GABA-T) with α-KG as cofactor to produce succinate 
semialdehyde (SSA) and glutamate (Figure 3.2.4). SSA is metabolized to succinate via SSA-
dehydrogenase (SSADH), which can then be incorporated back into the TCA cycle. This 
anaplerotic addition of succinate compensates the cataplerotic loss of carbons from the generation 
of glutamate by the GABA-T (Figure 3.2.1) (Schousboe et al., 2013).  
 In addition to metabolism, evidence indicates that astrocyte mitochondrial bioenergetics 
are important for the regulation of neurotransmitter balance. Both glutamate and GABA uptake 
systems in astrocytes are driven by Na
+
 gradients that are established by the electrogenic action of 
the sodium-potassium adenosine triphosphatase (Na
+
/K
+ 
ATPase) (Figure 3.3.4). PC and GS 
activities also require ATP as well, and are critical enzymes in replenishing neuronal 
glutamine/glutamate (Figure 3.2.1 and 3.3.4). Importantly, it has been demonstrated that 
mitochondria co-localize with EAAT1/2 on the plasma membrane of astrocytes as well as with 
glycolysis enzymes (Genda et al., 2011;Bauer et al., 2012) and glutamate transporters physically 
interact with the Na
+
/K
+
 ATPase (Figure 3.3.6) (Rose et al., 2009), suggesting that while 
mitochondrial-derived ATP is not required for astrocyte survival (Supplie et al., 2017), functional 
mitochondrial metabolism is important for neurotransmitter uptake and homeostasis (Figure 
3.3.2, 3.3.4 and 3.3.6). In fact, astrocyte processes enveloping synaptic terminals contain 
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abundant mitochondria (Jackson et al., 2014;Stephen et al., 2015;Jackson and Robinson, 2018), 
and inhibition of mitochondrial function by fluorocitrate in astrocytes increases glutamate 
excitotoxicity in co-cultures with neurons (Voloboueva et al., 2007). 
3.6 Mitochondrial Metabolism in Astrocytes and Redox balance 
 Astrocytes have less efficient mitochondrial respiration and increased ROS formation 
when compared to neurons, in part due to a lower incorporation of complex I into 
supercomplexes in astrocytes caused by lower expression of the NADH-ubiquinone 
oxidoreductase core subunit S1 (NDUFS1) (Lopez-Fabuel et al., 2016).  Regardless, scientific 
literature indicates that neurons have limited defense mechanisms against ROS compared to 
astrocytes. While both neurons and astrocytes can synthesize GSH, astrocytes have been reported 
to protect neurons via regulation of GSH metabolism (Chen et al., 2001;Shih et al., 2003). This 
protective effect is thought to be dependent on the supply of cysteine from astrocytes as a 
precursor for de novo GSH synthesis (Dringen et al., 1999;Wang and Cynader, 2000), and in part 
due to neurons being unable to uptake significant extracellular cystine (Sagara et al., 
1993;Kranich et al., 1996). GSH has been proposed to be released from astrocytes via the ATP-
binding cassette transporters subfamily C member 1 transporter (ABCC1, or multidrug-
resistance-associated protein 1 [MRP1]) (Figure 3.1.6 and 3.3.2) (Hirrlinger et al., 
2002;Hirrlinger and Dringen, 2005). Indeed, inhibition of MRP1 has been reported to reduce the 
extracellular accumulation of GSH in cultured astrocytes (Hirrlinger and Dringen, 2005). We 
have failed to observe a reciprocal accumulation of GSH in astrocytes when MRP1 activity is 
reduced (unpublished data), but this effect might be ascribed to feedback inhibition of GSH 
synthesis by GSH.   
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 Once released, GSH is degraded by the γ-glutamyl transpeptidase (γGT) to produce l-
cysteine-l-glycine (CysGly) (Dringen et al., 1997). CysGly is cleaved further by the neuronal 
aminopeptidase N (ApN) into the amino acids glycine and cysteine that are taken up by neurons 
for de novo GSH synthesis via GlyT1 and EAAT3, respectively (Figure 3.3.2 and 3.3.3) 
(Dringen et al., 1999;Dringen et al., 2001;Aoyama et al., 2008;Belanger et al., 2011). The export 
of GSH should imply a loss of carbons that must be replenished in astrocytes to maintain 
cellular redox homeostasis. Cysteine acquisition in astrocytes is mediated by Na
+
-dependent 
and -independent uptake systems, but the exact contribution of XAG-/EAAT3 and Xc-/xCT 
systems is still under debate (Shanker et al., 2001;Seib et al., 2011).  De novo synthesis via the 
trans-sulfuration (TSP) pathway is also an important source for cysteine in astrocytes, and was 
shown to be upregulated and utilized during oxidative stress (Figure 3.3.2) (Vitvitsky et al., 
2006). In most cells, cysteine is considered the limiting substrate for GSH synthesis. However, 
because glutamate in astrocytes is also metabolized to glutamine, it might also be considered a 
limiting factor (Figure 3.1.6). Because glutamate synthesis depends on mitochondrial 
anaplerotic metabolism, mitochondrial function might also be essential for GSH homeostasis 
(Figure 3.2.1 and 3.2.4). Interestingly, GSH depletion upregulates mitochondrial activity and 
expression of complex I in astrocytes (Vasquez et al., 2001), but the exact mechanisms that 
regulate this phenomenon are still unclear. 
3.7 Conclusions and perspectives 
 The scientific process has been aptly described as blind people attempting to describe an 
elephant while only focusing on particular parts of the animal. Each person is contextually 
correct, but only when the data is combined can we achieve an accurate understanding of the 
whole. While there are far more parts of the proverbial elephant to explore to complete the 
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picture, the recent evidence indicates that we must adjust our current understanding of brain 
metabolism, particularly as it pertains to astrocytes and neurons. 
 Current research indicates that metabolism in the brain extends far beyond glucose. Fatty 
acids, and their derived ketone bodies, are important sources of bioenergetic potential for the 
brain, particularly during development, as shown by the experiments in vivo and in vitro that 
follow its oxidation and integration into biomolecules. Glutamate is more than just a 
neurotransmitter kept in strict stoichiometry by the glutamate-glutamine cycle; it is a resource the 
brain uses for amino acid synthesis by transamination, for redox balance by generation of 
NADPH, and for anaplerosis to maintain the TCA cycle. 
 The brain is far from a homogeneous body of cells, and the literature paints a clear 
picture of metabolic specialization and intracellular cooperation/dependence. In this chapter, we 
have centered our attention to astrocytic mitochondrial metabolism and its role in the regulation 
of brain bioenergetics, neurotransmission and redox balance via neuronal-astrocyte metabolic 
interactions. Astrocytes have been demonstrated to be functional without OXPHOS in vivo, to 
provide a GSH-dependent protective effect to neurons, to function as neutralizing and cycling 
agents of glutamatergic/GABAergic signaling, and to be synthesizers/exporters of OXPHOS 
bioenergetic molecules (lactate/ketone bodies). In contrast, neurons have a metabolic 
specialization towards OXPHOS, spurning FAO, restricting glucose oxidation while maintaining 
the PPP for redox homeostasis, and limiting their ability to conduct mitochondrial biosynthesis 
due to a lack of pyruvate carboxylase for anaplerosis. Together, neurons shoulder the bioenergetic 
burden of neurotransmission by controlled alterations in cell potential, while astrocytes conduct 
biosynthesis and high ROS oxidative processes to supplement neuronal functions. 
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 The key organelle in this differential specialization is the mitochondria. While the broad 
mitochondrial role in OXPHOS is well known in mammalian cells, specialization is evident 
within neurons and astrocytes. Astrocytes restrict the conversion of pyruvate to acetyl-CoA by 
their phosphorylation of PDH, limiting their utilization of glucose for OXPHOS but instead 
directing these carbons to biosynthesis through the TCA cycle by PC. Additionally, the efficiency 
of the astrocyte ETC is far less than neurons, resulting in higher ROS generation in astrocyte 
compared to neurons. Astrocytic mitochondria have been demonstrated to utilize FAO for the 
production of ketone bodies, a process that has not been shown to be significant in neurons. 
Further, evidence shows that astrocytes localize mitochondria to endfeet processes in conjunction 
with glutamate transporters and enzymes related to glycolysis. Coupled with the evidence that 
OXPHOS is not required in astrocytes in vivo, this paints a unique picture for astrocyte 
mitochondria compared to the prototypical mammalian cell. It is a mitochondria specializing in 
synthesis at the expense of OXPHOS, while the neuronal mitochondria specialize in OXPHOS at 
the expense of synthesis. 
 
 
 
 
 
 
 
57 
 
3.8 List of Abbreviations 
2-HPCL  2-hydroxyphytanoyl-CoA lyase  
3-OHacyl-CoA  3-hydroxyacyl-Coenzyme A 
ABCC1/MRP1 
 adenosine-triphosphate-binding cassette transporter subfamily C member 1 or 
multidrug-resistance-associated protein 1 
ABCD1  adenosine triphosphate binding cassette subfamily D member 1 
AcAc  Acetoacetate  
ACAT  acetyl-CoA C-acetyltransferase, acetoacetyl-CoA thiolase II  
ACC  acetyl-CoA carboxylase 
ACD  acyl-CoA dehydrogenase  
ACS  acyl-CoA synthetase 
AGC  aspartate/glutamate carrier antiporter or Aralar 1  
G  -ketoglutarate 
ALAT  alanine aminotransferase  
ALDP  adrenoleukodystrophy protein  
AMPK  adenosine monophosphate activated protein kinase  
ANLS  astrocyte-neuron lactate shuttle  
ANT  adenine nucleotide transporter 
ApN  aminopeptidase N  
ApoE/D  apolipoprotein E/D 
ATP  adenosine triphosphate 
BBB  blood-brain barrier  
BCAA  branched chain amino acids  
BCAT  branched chain aminotransferases  
BDH  β-hydroxybutyrate dehydrogenase  
CACT  carnitine/acylcarnitine translocase  
cAMP  cyclic adenosine monophosphate 
CAT  catalase  
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CIC  citrate isocitrate carrier  
CNS  central nervous system  
CNTF  ciliary neurotrophic factor  
CoA  coenzyme A  
CPT  Carnitine palmitoyltransferase  
CysGly  l-cysteine-l-glycine (CysGly)  
EAAT  excitatory amino acid transporter  
ECH  enoyl-CoA hydratase   
ETC  electron transport chain  
ETF  electron transferring flavoprotein  
F2,6BP  fructose-2,6-bisphosphate 
FA  fatty acid 
FADH2 flavin adenine dinucleotide 
FAO  fatty acid oxidation  
FAT/CD36  fatty acid translocase  
FATP  fatty acid transport protein  
GABA  γ-aminobutyric acid  
GABA-T  γ-aminobutyric acid transaminase  
GAD  glutamate decarboxylase  
GAT  γ-aminobutyric acid transporter  
GC1  glutamate carrier or SLC25A22 
GDH  glutamate dehydrogenase  
GFAP  glial fibrillary acidic protein  
GLAST  glutamate aspartate transporter or excitatory amino acid transporter 1  
GLT-1  glutamate transporter 1 or  excitatory amino acid transporter 2 
GOT1  cytosolic aspartate aminotransferase 
GOT2  mitochondrial aspartate aminotransferase  
GS  glutamine synthetase  
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GSH  glutathione 
HAD  3-hydroxyacyl-Coenzyme A dehydrogenase    
HMCS1  β-hydroxy-β-methyl glutaryl (HMG)-CoA synthase  
HMGCL  HMG-CoA lyase  
IP3  inositol triphosphate,  
LCFA  long chain fatty acid 
MCFA  medium chain fatty acids  
MCT  monocarboxylate transporter  
MPC  mitochondrial pyruvate carrier 
Na
+
/K
+
 ATPase  sodium-potassium adenosine triphosphatase 
NADH  nicotinamide adenine dinucleotide 
NADPH  nicotinamide adenine dinucleotide phosphate  
NDUFS1  nicotinamide adenine dinucleotide ubiquinone oxidoreductase core subunit S1 
OXPHOS  oxidative phosphorylation  
PAG  phosphate-activated glutaminase  
PC  Pyruvate carboxylase  
PDH  pyruvate dehydrogenase  
PEP  phosphoenolpyruvate  
PEPCK  phosphoenolpyruvate carboxykinase  
PFK1  phosphofructokinase 1  
PFKFB3  6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3  
PhyH/Pahx  phytanoyl-CoA hydroxylase  
PPAR  peroxisome proliferation activated receptor  
PPP  pentose phosphate pathway  
PUFA  poly-unsaturated fatty acid  
Redox  reduction-oxidation 
RET  reverse electron transfer  
ROS  reactive oxygen specie 
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SCFA  short chain fatty acids  
SCOT  succinyl‐CoA‐3-oxoacid-CoA transferase 
SNAT  sodium-coupled neutral amino acid transporter  
SSA  succinate semialdehyde  
SSADH  succinate semialdehyde dehydrogenase  
TCA cycle  tricarboxylic acid or Krebs cycle 
TSP  transsulfuration pathway 
VDAC  voltage-dependent anion channel  
VLCFA  very long chain fatty acid 
XAG-/EAAT3  aspartate-glutamate transporter 
βHB β-hydroxybutyrate 
γGT  γ-glutamyl transpeptidase  
Xc-/xCT cystine-glutamate exchanger 
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CHAPTER 4  
ASTROCYTES DEPEND UPON MITOCHONDRIA DURING ARSENIC EXPOSURE 
 
4.1 Introduction 
As discussed in chapters 2 and 3, astrocytes and neurons perform specialized metabolic 
functions for synaptic transmission, with astrocytes primarily maintaining homeostasis. Astrocyte 
processes envelope the capillary blood brain barrier (BBB) (Mathiisen et al., 2010), and become 
the first central nervous system (CNS) cells to encounter toxic compounds entering the brain. 
While numerous studies have documented the effects of xenobiotics on neuronal function, far 
fewer have delved into the effects of xenobiotics on astrocytes. While astrocytes have 
demonstrated resilience in the face of xenobiotic challenges compared to other CNS cell types 
(Hollensworth et al., 2000;Rathinam et al., 2012), how astrocyte metabolism changes to 
compensate for xenobiotic exposure has not been fully explored. In particular, the role of 
mitochondrial metabolism in astrocytes has often been overlooked, in part because of the 
aforementioned resilience of astrocytes to xenobiotic challenges and the demonstrated glycolytic 
nature of astrocytes (Supplie et al., 2017). Given the interconnected nature of astrocyte-neuron 
metabolism, it is imperative to understand what metabolic alterations are induced in astrocytes by 
xenobiotics to understand how xenobiotic toxicity affects neurotransmission. 
Arsenic is a metalloid element with a widespread, variable distribution throughout the 
Earth’s crust. The high aqueous solubility of inorganic arsenicals allows for high groundwater 
contamination (Nordstrom, 2002;Duker et al., 2005). One of the best documented exposure to 
arsenic contaminated water occurred in the 1980s in Bangladesh, when shallow wells were 
constructed to increase access to clean water. The issue went largely unaddressed until 1998, and 
water analysis revealed that 34.9% of the 19,845 wells of the flood plains had arsenic 
contamination above the World Health Organization’s (WHO) maximum permissible limit of 50 
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µg/L, with the highest measured concentration being 4730 µg/L (Chakraborti et al., 2015). No 
level of arsenic contamination is without risk, as illustrated in a study of verbal, intellect quotient, 
and long term memory on Bangladeshi children found that the inverse correlation between each 
test and arsenic water contamination could be observed even between 0.1-5.5ug/L and 5.6-50ug/L 
groups (Wasserman et al., 2004). Further, arsenic associated skin lesions have been reported 
following chronic exposure to water containing less than 10ug/L of arsenic (Ahsan et al., 
2000;Ahsan et al., 2006), however the link to skin cancer at these concentrations is still debated 
(see (Hong et al., 2014) for a review on chronic arsenic exposure symptoms). The arsenic 
contaminated water was also used in irrigation, and an ensuing analysis of regions with high 
arsenic contamination (200-500 µg/L) found a mean arsenic accumulation of 358 µg/kg and 333 
µg/kg in rice and vegetables, respectively. Further, 87% of the arsenic in rice and 96% of the 
arsenic in vegetables were in inorganic forms (Smith et al., 2006). Arsenicals, such as p-arsanilic 
acid and nitarsone, that are not readily absorbed into animals are used in animal feed to mitigate 
protozoan infections and are excreted. However, when manure from these animals is used as 
fertilizer, the arsenicals are absorbed into agricultural products such as rice. The plants then 
convert the arsenicals into forms that are readily absorbed and toxic to animals, such as arsenite 
(As
III
), monomethylarsonic acid (MMA), dimethylarsinic acid (DMA), and arsenate (As
V
) (Geng 
et al., 2017).  
Inorganic arsenic typically exists in two oxidation states, the pentavalent arsenate (As
V
) 
that predominates in oxygenated or oxidizing environments, and the trivalent arsenite (As
III
) that 
predominates in reductive environments (Duker et al., 2005). Arsenite enters the cell through 
aquaglycoporins (Liu et al., 2004) and glucose transporters (Liu et al., 2006), while arsenate 
enters through phosphate transporters (Villa-Bellosta and Sorribas, 2010). Early studies on 
mammalian arsenic exposure revealed that DMA and MMA in the pentavalent form (DMA
V
 and 
MMA
V
) were present in urine. DMA
V
 and MMA
V
 displayed reduced cytotoxicity, but were later 
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found to possess carcinogenic properties. It was later discovered that the trivalent forms of the 
metabolites (DMA
III
 and MMA
III
) were also present in urine and were more carcinogenic than the 
pentavalent forms (reviewed in (Drobna et al., 2009)). Further, the principal enzyme in 
methylation of inorganic arsenic in humans, arsenic methyltransferase (AS3MT), uses trivalent 
arsenicals as a substrate. Further, methylation is promoted in the presence of GSH and reductases 
(Waters et al., 2004), reinforcing the proposed model whereby arsenicals alternate their oxidation 
state during methylation (Challenger, 1947). Further supporting this notion is the observed 
preference for glutathionylated arsenicals  by AS3MT (Hayakawa et al., 2005), and the discovery 
of glutathionylated arsenicals in the urine of mice deficient in ɣ-glutamyltranspeptidase 
(ɣGT)(Kala et al., 2004). 
 In the brain, AS3MT has been shown to be highly expressed in astrocytes compared to 
neurons (Li et al., 2016), but it has also been reported that cultured astrocytes do not produce 
significant quantities of methylated arsenic species (Koehler et al., 2014). Nevertheless, the 
literature also indicates that methylated arsenic is produced in brain slices exposed to arsenic 
(Rodriguez et al., 2005), and that astrocytes are highly resistant to the effects of methylated 
arsenicals (Jin et al., 2004;Meyer et al., 2013). This methylation vs. glutathionylation distinction 
is important, as a methylation process with a glutathionylated arsenical intermediate would be 
expected to release GSH, or a derivative of GSH, back into the intra- or extracellular 
compartments. Further, triglutathionylated arsenical has been proposed to be exported by MRP1 
(Leslie et al., 2004). However, this experiment was performed in HeLa cells and MRP1 has 
altered substrate specificity and kinetics depending on cell type (Banerjee et al., 2018), and 
corresponding post-translational modifications (Shukalek et al., 2016).  
The importance of determining the mechanism of arsenic toxicity in the cells of the CNS 
is underscored by the neurodegenerative and cognitive impairment observed with chronic arsenic 
exposure. Multiple inverse correlations have been found between intelligence quotient (IQ) 
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parameters and environmental arsenic exposure during childhood (Rosado et al., 2007;Dong and 
Su, 2009;Hamadani et al., 2011;Wasserman et al., 2014). How this occurs has not been 
determined, though there is evidence that arsenic exposure alters neurotransmitter homeostasis 
(Yadav et al., 2010;Jiang et al., 2014;Ramos-Chavez et al., 2015), long term potentiation (Kruger 
et al., 2009), and mitochondrial function (Hu et al., 1998;Prakash et al., 2015). Arsenic has also 
been proposed to induce the production of reactive oxygen species (ROS) in the brain, 
particularly in neurons (Piao et al., 2005;Dwivedi and Flora, 2011;Flora, 2011;Prakash and 
Kumar, 2016), as well as alter the expression of excitatory amino acid transporters (Castro-
Coronel et al., 2011;Zhao et al., 2012). 
The effects of arsenic induced mitochondrial dysfunction have been difficult to elucidate. 
Isolated rat liver mitochondria have been shown to reduce arsenate to arsenite in a manner that is 
dependent upon electron transport chain activity (Nemeti and Gregus, 2002). Further, arsenite, 
and to a lesser extent methylated arsenite species, have been shown to inhibit both purified 
pyruvate dehydrogenase  activity by binding to the reduced lipoic acid moieties 
(Bergquist et al., 2009). In line with this observation, arsenite exposure has been shown to reduce 
mitochondrial complex activities and oxygen consumption, while increasing the mutation rate of 
nuclear and mitochondrial DNA in a manner dependent upon mitochondrial activity (Liu et al., 
2005;Partridge et al., 2007;Hosseini et al., 2013). The DNA damage does not appear to be a direct 
effect of arsenic on DNA repair enzymes (Hu et al., 1998). Instead, DNA damage may be indirect 
effect of the ROS generated from arsenic exposure (Ramanathan et al., 2003;Hosseini et al., 
2013;Prakash et al., 2015). However, ROS may not be directly produced by arsenic, and it has 
been proposed that GSH depletion during arsenite exposure is the source of the observed ROS 
(Han et al., 2008). 
 In this chapter, arsenic was used as a representative xenobiotic to explore alterations to 
astrocyte metabolism during xenobiotic exposure. The experiments confirm previous reports that 
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astrocyte arsenic detoxification is glutathione (GSH) and multi-drug resistance associated protein 
1 (MRP1) dependent, and that astrocytes remain viable when challenged with mitochondrial 
toxins. The experiments highlight that astrocyte viability is compromised during arsenic exposure 
by the loss of mitochondrial functions, inhibition of mitochondrial carbon inputs from pyruvate 
and fatty acids, and loss of aminotransferase activity. Further, arsenic exposure causes astrocytes 
to efflux glutamate to the media, generating extracellular glutamate concentrations that would be 
considered excitotoxic to neurons. 
 
4.2 Materials and Methods 
4.2.1 Cell Culture 
 Primary cortical astrocytes from post-natal day 1-2 C57Bl/6 mice were obtained from 
stocks previously frozen by Dr Annadurai Anandhan and Dr Carla Garza-Lombo, following the 
protocol of (Waagepetersen et al., 2002). Astrocytes were cultured in Dulbecco's Modified Eagle 
Medium with nutrient mixture F-12 (DMEM:f12, Hyclone) supplemented with 10% fetal bovine 
serum (FBS, Atlanta Biologicals), and 200 U/ml penicillin + 200 μg/ml streptomycin (P/S, 
Lonza). Cultured astrocytes were kept at 37°C in 5% carbon dioxide (CO2) humidified incubator. 
Astrocytes were used up to the third passage. 
 
4.2.2 Flow Cytometry 
 Astrocytes were seeded into 12-well plates at a density of 84,000 cells/ml. Fresh media 
supplemented with treatments was provided once the astrocytes reached 95% confluency. Cells 
were treated for 48hrs under the conditions above. Cell viability was determined with propidium 
iodide uptake (PI, 1 μg/ml) (Life Technologies) detecting loss of plasma membrane, and 
monochlorobimane (mBCl, 10 μM) (Molecular Probes) measuring intracellular GSH content. 
Flow cytometry was performed as described previously (Anandhan et al., 2017). 
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4.2.3 ICP-MS  
 Astrocytes were seeded into 12-well plates at a density of 84,000 cells/ml in DMEM:f12 
supplemented medium as described above. Fresh DMEM:f12 supplemented with treatments was 
provided once the astrocytes reached 95% confluency. At the indicated time points, the media 
was removed and the cell trypsinized. Twice, the cells were pelleted, the supernatant removed, 
and the pellet gently resuspended in phosphate buffered saline (PBS). Half of each sample was 
then sent for ICP-MS, while the other half was used for normalization by a Pierce bicinchoninic 
acid (BCA) protein assay (Thermo). ICP-MS was performed as per (Anandhan et al., 2015). 
 
4.2.4 Glutamate Quantification 
 Astrocytes were seeded into 12-well plates at a density of 84,000 cells/ml in DMEM:f12 
supplemented medium as described above. Once the astrocytes reached 95% confluency, the cells 
were washed with prewarmed PBS and given Neurobasal A media supplemented with 1% B27, 
2.5 mM glutamine and treatments for 24 hrs. The Neurobasal A media was removed and the 
sample was centrifuged at 300 g for 5 mins to pellet and remove any loose cells. Neurobasal 
media was then used in a Glutamate-Glo kit (Promega) as per manufacturer’s instructions for 50 
µl of samples. Media samples were diluted fourfold in PBS to keep measurements within the 
linear range of the kit. Results were normalized to total media volume at the time of collection, 
and to total protein content of the cells by a Pierce bicinchoninic acid (BCA) protein assay 
(Thermo). 
 
4.2.5 ATP Quantification 
 Astrocytes were seeded into 96-well plates at a density of 7000 cells/well in DMEM:f12 
supplemented medium as described above. Fresh DMEM:f12 supplemented with treatments was 
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provided once the astrocytes reached 95% confluency. After 24 hrs of treatment, Cell-Titer Assay 
(Promega) was performed as per manufacturer’s instructions to quantify the total ATP content of 
each well. 
 
4.2.6 Seahorse Mitochondrial Oxygen Consumption 
Oxygen consumption (OCR, pmol/min) was determined using XFe24 Analyzer (Seahorse 
Biosciences) as per (Anandhan et al., 2017) with modifications outlined below. Astrocytes were 
grown to confluency in DMEM:f12 supplemented media as previously described and before 
additional media containing treatment factors was added. Treatment occurred in a CO2-less 
incubator at 37°C for 24 hrs. After treatment, cells were washed and incubated for 1hr in HCO3 
and 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) free DMEM (Gibco) 
supplemented with 2.5 mM glutamine, 17.5mM glucose, 1mM pyruvate and treatment factors 
prior to OCR measurements. OCR measurements were conducted using a final concentration of 
1µM oligomycin, 1µM carbonyl cyanide m-chlorophenyl hydrazone (CCCP), and a mixture of 
0.5 µM rotenone and 0.5 µM antimycin A. Measurements were normalized to total protein 
concentration. OCR was used as an indicator of mitochondrial function and capacity, as described 
by the manufacturer’s protocols. 
 
4.2.7 NMR Metabolomics  
 Astrocytes were seeded onto 100 mm dishes at a density of 1.2x10
6
 cells/9ml. Upon 
reaching 95% confluency, cells were washed twice with 1 ml prewarmed PBS. DMEM media 
supplemented with 17.5 mM U-
13
C glucose, 1 mM pyruvate, and 2.5 mM glutamine in addition to 
10% FBS and P/S, and sodium arsenite. For glutamate metabolomics, 17.5 mM unlabeled 
dextrose was used, and 100 µM U-
13
C/
15
N glutamate was added. Following 24 hrs, cells and 
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media were collected by Jade Woods and Alexandra Crook, with 2D 
1
H-
13
C NMR HSQC 
experiments were performed as per (Bhinderwala et al., 2019). 
 
4.3 Results 
4.3.1 Arsenic Exposure Creates a Reduced Intracellular State 
Previous reports have implicated the glutathionylation of arsenicals in the detoxification 
process of many mammalian cell types, including astrocytes, that is either directly excreted or 
converted to a methylated arsenical for export (Cui et al., 2004;Leslie et al., 2004;Hayakawa et 
al., 2005). Flow cytometry was used to measure intracellular GSH and membrane integrity of 
astrocytes with various arsenic concentrations.  In this regards, the results were used to determine 
if the loss of GSH was a measurable characteristic of arsenic toxicity by flow cytometry. Viable 
cells were defined as cells that are mBCl positive and PI negative. Preliminary data from 
Anandhan Annadurai showed that GSH depletion proceeded loss of membrane integrity (Figure 
4.1A). In line with previous reports, low concentrations of arsenic increased the intracellular GSH 
concentration compared to the non-treated controls (Figure 4.1B).  
 
4.3.2 Arsenic Exposure Increases Glutamate Synthesis from Glucose 
 Nuclear magnetic resonance (NMR) was used to create a metabolomic profile of 
astrocytes cultured with U-
13
C-glucose at the previously utilized arsenic concentrations by 
Anandhan Annadurai and Shulei Lei. As shown in Figure 4.2A, the intracellular compartment 
demonstrated a significant fold increase in 3-phosphoglycerate (a precursor to both glycine and 
cysteine synthesis) during arsenic exposure. Conversely, the concentration of fructose-6-
phosphate first decreased at low arsenic concentrations and then increased at higher arsenic 
concentrations. Notably, intracellular lactate remained initially constant and only decreased at the 
highest arsenic concentrations, while UDP-glucose decreased at all tested arsenic concentrations.  
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Figure 4.1: Intracellular REDOX state of Astrocytes exposed to Arsenic 
(A) Flow cytometry performed on astrocytes following 48hrs of the indicated arsenic treatment. (B) 
Quantification of the fold change in mBCl signal in the dashed boxes of (A). *: p<.05 by student T-test. 
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While cysteine was not sufficiently labeled from U-
13
C-glucose to detect by NMR, and
 
glycine 
remained relatively constant, intracellular glutamate concentrations did decrease significantly at 
higher arsenic concentrations. 
Additionally, the culture media was analyzed for the presence of 
13
C-labeled products. As 
shown in Figure 4.2B, the efflux of both 
13
C-labeled lactate and citrate significantly increased at 
low levels of arsenic exposure, while being reduced at high arsenic concentrations. Unexpectedly, 
the extracellular concentration of labeled glutamate, not glutamine, dramatically increased during 
arsenic exposure. This contrasts with the intracellular data, but indicates that glucose carbons may 
be shuttled to glutamate production and exported by some undetermined process.  
 
4.3.3 Astrocyte Viability is Limited by GSH Synthesis, not GSH Recycling, during Arsenic 
Exposure 
 Due to ROS being a hallmark of arsenic exposure, and the incompletely defined role of 
GSH in arsenic detoxification, it was important to address whether the survival limiting aspect is 
GSH de novo synthesis or REDOX cycling of an existing GSH pool. If GSH is being used 
principally in a consumptive process during arsenic exposure, such as in forming a stable 
complex with arsenic and being excreted, inhibition of de novo GSH synthesis by buthionine 
sulphoximine (BSO) would greatly sensitize astrocytes to arsenic. However if GSH was instead 
being principally used as a reducing agent for arsenic derived ROS, then inhibition of the pentose 
phosphate pathway (PPP) by 6-aminonicotinamide (6-AN) would be expected to sensitize 
astrocytes to arsenic by limiting the ability to reduce oxidized glutathione (GSSG) to GSH 
(Figure 4.3C). While 6-AN had no significant effect on cell viability (Figure 4.3A), BSO 
dramatically sensitized the astrocytes to arsenic while having minor effects on viability when 
administered alone (Figure 4.3B). Both compounds were also tested against hydrogen peroxide 
treatment, demonstrating that each compound reduced cell viability in the presence of reactive 
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Figure 4.2: 2D-NMR Metabolomics with U-
13
C-glucose  
2D-NMR (
1
H-
13
C) metabolomics performed on astrocytes treated with the indicated arsenic concentrations 
in media containing 17.5mM U-
13
C-glucose for 24hrs. Cellular (A) and media (B) components were 
measured for each sample and represented as fold change compared to control. (C) Pathway model of the 
results from (A-B). *: p<.05 by One Way ANOVA compared to untreated control. 
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Figure 4.3: Inhibition of GSH synthesis and REDOX cycling during Arsenite Exposure 
(A-B) Viable cell population determined by flow cytometry following 48hrs of sodium arsenite or 
hydrogen peroxide, vs. 1mM 6-AN (A) or .5mM BSO (B). (C) Graphical representation of GSH pathways 
and the inhibitors used. a,b: p<.05 Two Way ANOVA vs. the untreated control (a) or the control at the 
same arsenic/peroxide concentration (b). 
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oxygen species (ROS) (Figure 4.3A-B). These results provide evidence that arsenic 
detoxification involves a process that consumes GSH, and implies that glutathionylation of 
arsenic and/or GSH efflux is a significant effect in astrocytes during arsenic exposure. 
 
4.3.4 Astrocyte Arsenic Detoxification is Dependent upon MRP1  
The accumulation of intracellular arsenic within astrocytes was determined in order to 
approximate a tipping point for detoxification. Utilizing inductively coupled plasma mass 
spectrometry (ICP-MS) a time course of intracellular arsenic accumulation in astrocytes was 
established for 5, 10, and 20 µM sodium arsenite (NaAsO2) exposure over a 24hr period. 10 µM 
sodium arsenite (NaAsO2) established an approximate equilibrium between efflux and influx 
(Figure 4.4A), while 5 µM sodium arsenite did not show significant arsenic accumulation beyond 
the 6hr time point. As MRP1 has been previously implicated in the efflux of glutathionylated 
arsenicals (Leslie et al., 2004), astrocyte viability and intracellular arsenic accumulation was 
measured in the presence of an MRP1 inhibitor (MK571). In contrast with previous results 
(Tadepalle et al., 2014), MK571 sensitized astrocytes to arsenite (Figure 4.4B), though the 
increase in intracellular arsenic accumulation (Figure 4.4C) is consistent with that study. MK571 
was not found to have an effect on viability during peroxide treatment (Appendix Figure 1), 
reinforcing that MRP1 activity during arsenic exposure is not directly related to ROS production.  
 
4.3.5 Extracellular Glutamate Accumulates in Astrocyte Cultures Exposed to Arsenic  
 To corroborate the glutamate efflux in the NMR results, an enzymatic assay (Glutamate-
Glo, Promega) was performed to quantify the total glutamate in the astrocyte culture media. As 
the assay measures total glutamate, and not just glutamate produced by astrocytes, Neurobasal A 
media rather than DMEM was used following astrocyte confluency, as the DMEM media   
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Figure 4.4: ICP-MS Time Course of Intracellular Arsenic and MRP1 Inhibition 
(A) Intracellular arsenic accumulation time course by ICP-MS at the indicated arsenic exposures. α,ß,ɣ: 
p<.05 by Two Way ANOVA within a time point between: 20µM vs. 10µM (α), 20µM vs. 5µM (ß), and 
10µM vs. 5µM (ɣ). *: p<.05 by Two Way ANOVA between untreated cells and treated cells. (B) Viable 
cell population determined by flow cytometry following 48hrs of sodium arsenite vs. 25µM MK571. (C) 
Intracellular arsenic accumulation by ICP-MS after 24hrs at the indicated arsenic exposures vs. 25µM 
MK571. a,b: p<.05 Two Way ANOVA vs. the untreated control (a) or the control at the same arsenic 
concentration (b). 
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contained approximately 50 µM glutamate. As in the NMR experiment, the presence of arsenic 
dramatically increased the quantity of glutamate produced by astrocytes (Figure 4.5A).  
 
4.3.6 Extracellular Glutamate Accumulation is not dependent on MRP1 or ɣGT 
As described in chapter 2, astrocytes produce GSH for neurons, which is broken down by 
astrocyte ɣ-glutamyltranspeptidase (ɣGT) and neuronal aminopeptidase N (ApN) into its amino 
acid components. Additionally, this astrocyte GSH export process and arsenic detoxification are 
both dependent upon MRP1 (Figure 4.4B-C). Enzymatic quantification of extracellular 
glutamate from astrocytes given ɣGT (Acivicin) or MRP1 (MK571) inhibitors was used to 
determine if the decomposition of arsenic-GSH complexes or GSH were the sources of the 
extracellular glutamate, but no significant differences were observed (Figure 4.5A).  
 
4.3.7 Extracellular Glutamate Accumulates Independently of Arsenic during EAAT1/2  
Inhibition, but only EAAT1 sensitizes Astrocytes to Arsenic 
As excitatory amino acid transporters have been reported to reverse transport under 
certain conditions, inhibitors UCPH-101 (EAAT1) and WAY-213613 (EAAT2) were applied to 
astrocytes with or without arsenic, and found that significant glutamate accumulated outside of 
the cell independent of arsenic exposure. (Figure 4.5A). Given that intracellular glutamate 
decreased in the presence of arsenic (Figure 4.2A) and that EAAT1/2 inhibition increased 
extracellular glutamate accumulation (Figure 4.5A), it was important to determine if the function 
of EAAT1 and EAAT2 would sensitize astrocytes to arsenic. Administration of both UCPH-101 
and WAY-213613 caused a significant decrease in viability in the presence of arsenic (Figure 
4.5B). To test if this was a synergistic effect of both compounds or if one transporter was 
primarily responsible, the test was repeated with each inhibitor assayed independently, and  
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Figure 4.5: Extracellular Glutamate and Arsenic Sensitivity Impacted by EAAT Inhibition 
(A) Extracellular glutamate concentration measured by Glutamate-Glo following arsenic treatment vs. 
100µM acivicin, 25µM MK571, or a mixture of 10µM UCPH-101 and 10µM WAY213613. (B-D) Viable 
cell population determined by flow cytometry following 48hrs of sodium arsenite vs. (B) a mixture of 
10µM UCPH-101 and 10µM WAY213613, (C) 10µM UCPH-101, (C) 10µM WAY213613, or (D) 50µM 
SAS. *: p<.05 by Two Way ANOVA compared to the control at the same arsenic concentration. a,b: p<.05 
Two Way ANOVA vs. the untreated control (a) or the control at the same arsenic concentration (b). 
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demonstrated that the effect was due to EAAT1, with no significant effect observed with EAAT2 
inhibition (Figure 4.5C). 
 
4.3.8 Inhibition of xCT has Minor Sensitizing Effects on Astrocytes to Arsenic 
The cystine-glutamate antiporter (xCT) is a means to acquire the limiting component 
cysteine for GSH synthesis in astrocytes through glutamate efflux(Cho and Bannai, 1990;Allen et 
al., 2001;Allen et al., 2002;Seib et al., 2011). The increased extracellular glutamate accumulation 
(Figure 4.5A) and the necessity of GSH synthesis (Figure 4.3B) during arsenic exposure in 
astrocytes implies the xCT system may be required to maintain intracellular cysteine 
concentrations during arsenic exposure. However, only a small but significant increase in arsenic 
sensitivity was observed with the application of sulfasalazine (SAS) during arsenic exposure, 
indicating that xCT is not likely a critical factor (Figure 4.5D). Additionally, astrocyte viability 
was tested during arsenic exposure in media supplemented with cystine (200µM) or methionine 
(200µM), but no protective or sensitizing effect was observed (Appendix Figure 2A) 
 
4.3.9 Inhibition of Mitochondria or Transamination Sensitizes Astrocytes to Arsenic 
 While the route of glutamate efflux remains to be determined, the observed reduction of 
intracellular glucose labeled glutamate during arsenic exposure (Figure 4.2A) coupled with the 
arsenic sensitizing effect of EAAT1 inhibition (Figure 4.5D) implies that glutamate could be a 
limiting substance for astrocyte survival. Though the most direct route of glutamate procurement 
would be the deamination of glutamine through glutaminase, preliminary results have shown that 
the application of the glutaminase inhibitor BPTES had no significant effect on cell viability with 
and without the presence of arsenic (Suppl. Figure 2B). De novo synthesis of glutamate requires 
mitochondrial processes, and astrocytes were therefore challenged with mitotoxins to determine if 
mitochondrial inhibition altered arsenic sensitivity. In agreement with previous results (Rathinam 
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et al., 2012;Zhang et al., 2015), astrocytes remained viable in the presence of low concentrations 
of the mitochondrial toxins rotenone, paraquat (PQ), or 1-methyl-4-phenylpyridinium (MPP
+
), 
but each of these compounds sensitize astrocytes to arsenic (Figure 4.6A). Experiments were 
performed to determine whether electron transport chain or carbon input restrictions to the 
mitochondria impacted total ATP. ATP levels exhibited small but significant decreases when 
arsenic was co-administered with UK5099, etomoxir, or rotenone (Figure 4.6B). Carbon 
restriction to the mitochondria similarly sensitized the astrocytes to arsenic, while having no 
significant independent effect (Figure 4.6C). Additionally, astrocyte viability was tested in the 
presence of aminooxyacetic acid (AOAA), as transamination is a key component of glutamate 
synthesis. A similar arsenic sensitization occurred with AOAA (Figure 4.6C). 24hr time point 
ICP-MS experiments were then performed to determine if UK5099, etomoxir, or AOAA affected 
arsenic accumulation in astrocytes. While each compound increased arsenic accumulation, 
surprisingly, no significant effect was observed except for etomoxir (Figure 4.6D). Similarly, 
measurements of extracellular glutamate following compound treatments did not yield any 
significant changes compared to controls, except for etomoxir (Figure 4.6E). 
 
4.3.10 Etomoxir and Arsenic Co-administration Damages Mitochondrial Respiratory Capacity 
 Given that the mitochondria is providing a critical function in astrocyte survival during 
arsenic exposure (Figure 4.6A) and that etomoxir induces significant effects during arsenic 
exposure in total ATP (Figure 4.6B), viability (Figure 4.6C), and intracellular arsenic 
accumulation (Figure 4.6D), mitochondrial respiration was measured during arsenic and/or 
etomoxir exposure utilizing the Seahorse Mito Stress Test (Agilent). As shown in Figure 6, 
arsenic had minimal effects on mitochondrial respiration, with a small yet significant decrease in 
maximal respiration. Etomoxir treatment almost completely stopped astrocyte mitochondrial 
respiration, but only a small change in maximal respiration was observed.  Thus, mitochondrial 
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Figure 4.6: Mitochondrial Functions are Essential During Arsenic Exposure 
(A) Viable cell population determined by flow cytometry following 48hrs of sodium arsenite vs. 1µM 
rotenone, 50µM paraquat, or 2.5mM MPP
+
. (B) ATP quantified by Cell-Titer Glo with the indicated 
arsenic concentrations vs. 200µM etomoxir, 5µM UK5099, or 1µM rotenone.  
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(Figure 4.6: Mitochondrial Functions are Essential During Arsenic Exposure continued) 
(C-E) Viable cell population determined by flow cytometry (C), intracellular arsenic accumulation by ICP-
MS (D), and extracellular glutamate accumulation measured by Glutamate-Glo (E) at the indicated arsenic 
exposures vs. 200µM etomoxir, 5µM UK5099, or 5mM AOAA. *: p<.05 by Two Way ANOVA compared 
to the control at the same arsenic concentration. a,b: p<.05 Two Way ANOVA vs. the untreated control (a) 
or the control at the same arsenic concentration (b). 
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electron transport machinery is still intact in the presence of etomoxir. However, co-
administration of etomoxir with arsenic led to a cessation of mitochondrial respiration and a 
dramatic decrease in maximal respiration. The results imply that the electron transport 
capabilities of the mitochondria were effectively disabled by the co-treatment of arsenic and 
etomoxir. 
 
4.3.11
 13
C/
15N Glutamate NMR Preliminary: Arsenic Doesn’t Alter GSH Incorporation, but 
Increases Extracellular Glutamate and Intracellular Glutamine. 
Given that glutamate is being synthesized by glucose precursors (Figure 4.2) and 
effluxed to the extracellular space (Figure 4.5A and 4.6E), NMR samples were generated using 
U-
13
C/
15
N glutamate to determine if glutamate metabolism had been altered by the presence of 
arsenic. While the final data analysis is still pending, preliminary data indicate that glutamate 
carbons are being incorporated into lactate, glutamine, and GSH. However, the changes observed 
with arsenic treatment were an increase in extracellular glutamate and intracellular glutamine, 
with no observed changes in extracellular lactate or intracellular GSH.  (Appendix Figure 3). 
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Figure 4.7: Mito Stress Test during Arsenic and Etomoxir Exposure 
Seahorse Mito Stress Test performed in an XFe24 Analyzer. Astrocytes were treated with/without 200µM 
etomoxir and/or 10µM arsenite for 24hrs. Final well concentrations of applied inhibitors are 1µM 
oligomycin, 1µM CCCP, and a mixture of .5µM rotenone and .5µM antimycin A. *: p<.05 by Two Way 
ANOVA compared to control. 
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4.4 Discussion 
4.4.1 Astrocyte Arsenic Detoxification is Dependent upon GSH Biosynthesis and MRP1 
The preliminary data from the Dr Annadurai Anandhan indicated that lethal arsenic 
exposure causes GSH depletion, and that sub-lethal arsenic exposure increases the intracellular 
GSH content, in agreement with previous observations (Sagara et al., 1996;Koehler et al., 2014). 
Whether this loss of intracellular GSH was principally due to a net loss of intracellular GSH, or 
was being oxidized in a transitory, recyclable process remained to be determined. With 6-AN 
having a minimal effect, and BSO having such a dramatic effect on astrocyte viability, we are 
confident that GSH is being lost in a process related to arsenic exposure, either by formation of an 
As-GSX complex and/or by the direct efflux of GSH from the astrocytes.  
While As-GSX complex efflux has not been directly demonstrated in astrocytes to our 
knowledge, both GSH efflux (Hirrlinger et al., 2002;Hirrlinger and Dringen, 2005) and arsenic 
induced GSH efflux (Tadepalle et al., 2014) have been linked to MRP1 in astrocytes. We did not 
observe an increase in intracellular GSH with MRP1 inhibition (data not shown). The use of a 
time-course ICP-MS to quantify intracellular arsenic accumulation during arsenic exposure with 
and without MK571 provided two important pieces of information: (1) sodium arsenite 
concentrations can be divided into sub-lethal (5 µM), steady state (10 µM), and lethal (20 µM) 
dosages, and (2) reinforces that MRP1 inhibition directly increased arsenic accumulation within 
the astrocytes and sensitizes astrocytes to arsenic. This information allowed us to narrow 
subsequent experiments around the 10 µM exposure, and provided further evidence that MRP1 is 
directly or indirectly involved in the export of arsenic and not just GSH export for neuronal use. 
The increased arsenic accumulation with MK571 had been previously reported, but the prior 
study performed the measurement after a two hour exposure (Tadepalle et al., 2014), which our 
data indicates is within an acute response phase of arsenic exposure. We believe our results 
strengthen prior observations, and provide a foundation for the exploration of arsenic 
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accumulation at the later, chronic stages of exposure. Combined with the BSO/6-AN data, we 
believe that a glutathionylated arsenical, or an arsenical that relies on GSH as a co-substrate, is 
exported in an MRP1 dependent process. 
 
4.4.2 Arsenic Exposure Induces Excitotoxic Glutamate Accumulation in Astrocyte Cultures 
To our knowledge, a metabolomic profile comparison of primary cortical astrocytes with 
variable arsenic exposure has not been performed. Tracking the changes in carbon labeling 
allowed insights into how metabolism shifted in response to arsenic toxicity. Intracellular 
glutamate labeling depleted with increasing arsenic, while the opposite was observed 
extracellularly (Figure 4.2B and Figure 4.5A). Importantly, 
13
C-labeled glutamate was 
distinguishable from glutamine, which is the expected product of astrocytes for neurotransmitter 
recycling. The finding that glutamate was significantly produced from a glucose carbon source 
and was exported has profound implications for neurotransmission and neuronal viability.  The 
NMR experiments only provided estimates of relative metabolite concentration changes. 
Validation of the NMR glutamate efflux was performed by the Glutamate-Glo enzymatic 
kit, where arsenic treated astrocytes demonstrated a very high rate of glutamate production. As 
the DMEM:f12 media used in our experiments had ~50 µM of glutamate as part of its 
formulation (validated with a preliminary test of the DMEM:f12 media with Glutamate-Glo, data 
not shown), we utilized Neurobasal A medium supplemented with B27 and 2.5 mM glutamine (to 
match DMEM:f12 glutamine) in order to quantify astrocyte produced glutamate. Our results 
contrast with a previous report that found an approximate 1.5 µM increase in extracellular 
glutamate after a 24hr exposure of 10 µM sodium arsenite to primary cortical astrocyte cultures 
(Wang et al., 2012). At the same arsenic exposure, we repeatedly observed over 30 µM glutamate 
within the media. In fact, an exposure of only 5 µM of sodium arsenite yielded ~ 20 µM 
glutamate in the media. A Glutamate-Glo experiment was also performed with astrocytes in our 
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DMEM:f12 media (data not shown), showing that a 10 µM sodium arsenite treatment produced 
an additional 25 µM of glutamate over background. The extracellular space within the CNS has 
been measured to contain ~0.6 µM glutamate. Furthermore, excitotoxic effects have been 
observed in neurons cultured independently of astrocytes or in brain regions, like the 
hippocampus, at an extracellular glutamate concentration of 2-5 µM (Lipton and Rosenberg, 
1994;Mark et al., 2001;Chen and Lipton, 2006). Thus, our results have profound implications for 
neuronal viability. 
Initially, the extracellular glutamate was believed to be derived from the GSH or As-GSX 
complexes that efflux from MRP1, as ɣGT has been described as a means to recycle glutamate 
for GSH resynthesis in cancer cells during drug treatment (Rajpert-De Meyts et al., 
1992;Hochwald et al., 1996;Pompella et al., 2006;Ramsay and Dilda, 2014). But, the Glutamate-
Glo results for acivicin and MK571 indicate that GSH or As-GSX are not the source (Figure 
4.5A). One limitation of the acivicin experiment (Figure 4.5A) is the lack of a positive control to 
ensure its functionality. Nevertheless, it stands to reason that arsenic induced extracellular 
glutamate accumulation is due to a deficiency of astrocyte glutamate reuptake, and/or an 
induction of glutamate efflux that is not dependent on MRP1/ ɣGT.  
Two principal glutamate reuptake transporters in astrocytes are EAAT1/2, with a high 
localization near the synaptic cleft and capillary processes (Roberts et al., 2014), and the reversal 
of glutamate transport during membrane depolarization (Szatkowski et al., 1990). Crystal 
structures have shown that UCPH-101 inhibits EAAT1 allosterically by preventing the substrate 
translocation transition state (Canul-Tec et al., 2017), while WAY213613 is a competitive 
inhibitor of EAAT2 (Dunlop et al., 2005). Our results indicate that extracellular glutamate 
accumulation dramatically increases in the presence of EAAT1/2 inhibition (Figure 4.5B). 
Interestingly, extracellular glutamate significantly accumulated with EAAT1/2 inhibition 
independent of arsenic, which implies the process that causes glutamate loss in astrocytes is 
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active in a non-stress state. Furthermore, the results suggest that either EAAT1/2 counteracted 
this process or the inhibitors reverse glutamate transport in astrocytes.  
Another source of glutamate extrusion is the cystine/glutamate antiporter xCT. Cysteine 
has been described as the limiting substrate of GSH synthesis in many cell types, including 
astrocytes (Wang and Cynader, 2000;McBean, 2017). Astrocytes have also been found to 
preferentially utilize cystine over cysteine for GSH synthesis (Kranich et al., 1996). Accordingly, 
xCT may increase its activity to export glutamate to acquire cystine for this process. As shown in 
Figure 4.5D, SAS has a minor but significant sensitizing effect to arsenic in astrocytes. We also 
demonstrated that increasing the extracellular cystine or methionine concentrations did not alter 
astrocyte sensitivity to arsenic (Appendix Figure 2A).  
  
4.4.3 Mitochondrial Function is Integral to Astrocyte Viability in the Presence of Arsenic 
While our results do not reveal the means of glutamate efflux, the data strongly 
demonstrate a role for mitochondrial metabolism during arsenic exposure in astrocytes. The NMR 
experiments revealed the increased integration of glucose carbons into citrate and glutamate pools 
(Figure 4.2), which suggested mitochondrial metabolism must be involved. However, whether 
the increased glucose carbon integration into metabolic pathways for citrate and glutamate was 
serving a critical function during arsenic exposure remained unknown. We demonstrated that 
mitochondrial toxins (PQ) and complex I inhibition (Rotenone, MPP
+
) sensitized astrocytes to 
arsenic, and that astrocytes remained viable in the presence of these inhibitors in the absence of 
arsenic (Figure 4.6A). A previous study demonstrate that astrocytes are not dependent on Cox10 
in an in vivo model (Supplie et al., 2017). Thus, we do not believe this sensitization is due to a 
deficiency in OXPHOS derived ATP.  Co-administration of rotenone and 10/20 µM arsenic did 
result in a net decrease of 20% in the total ATP, though no differences were observed with either 
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independent treatment (Figure 4.6B). We can also conclude that pyruvate carbon entry into the 
mitochondria is required during arsenic exposure in astrocytes (Figure 4.6C). 
While it is clear that the mitochondria perform an integral function during arsenic 
exposure, the precise role cannot be definitively determined by our data. Nevertheless, our 
observations do allow for identifying potential mitochondrial functions critical for astrocytes 
during arsenic exposure. 
One possible response to arsenic exposure is the use of complex I to balance the 
NAD+/NADH ratio in the cytosol. Cancer cells have long been known to metabolize glucose to 
lactate (Warburg, 1956), and have demonstrated that their mitochondria were not required for 
ATP production (King and Attardi, 1989). The cancer cell proliferation reduction caused by 
oligomycin (an inhibitor of ATP synthetase) was shown to be reversed by low doses of the 
uncoupling agent FCCP (Sullivan et al., 2015). Additionally, cancer cells treated with complex 
I/III inhibitors (phenformin + piericidin/antimycin) demonstrated a metabolic shift that was 
dependent on exogenous pyruvate and a reversal of MDH1 and GOT1 directionality toward the 
production of aspartate (Birsoy et al., 2015). These experiments illustrated that NAD+/NADH 
balancing was a key mitochondrial function in cancer cells. FCCP allowed ETC activity to 
resume by removing mitochondrial hyper-polarization and exogenous pyruvate converting to 
lactate bioenergetically balanced the reductive MDH1/GOT1 path of aspartate synthesis. In a 
similar fashion, astrocytes may require complex I to regenerate NAD+ from NADH, as the 
-ketoglutarate from acetyl-CoA and oxaloacetate in the oxidative arm of the TCA 
cycle generates NADH from NAD+. Additionally, while the full conversion of glucose to lactate 
does not perturb the NAD+/NADH ratio, our NMR data demonstrate that some proportion of 
glucose carbons become glutamate, changing the NAD+/NADH ratio by reducing NAD+ to 
NADH via isocitrate dehydrogenase. Therefore, complex I in the mitochondria of astrocytes may 
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primarily act as an electron sink during arsenic exposure in order to maintain the NAD+/NADH 
ratio by oxidizing NADH to NAD+ rather than to generate ATP. 
The loss of viability during arsenic exposure when administering UK5099 or etomoxir 
indicates that carbon entry into the mitochondria is vital. Unlike cancer cell studies (Birsoy et al., 
2015;Sullivan et al., 2015), glutamate rather than aspartate seems to be the destination for the 
pyruvate carbons entering the mitochondria. Citrate has been previously observed as an 
alternative carbon entry into the mitochondria for astrocytes (McKenna et al., 1995;Vogel et al., 
1998)) (Figure 3.1 and 3.2). Besides Seahorse related assays, very few studies have applied 
UK5099 to astrocytes, presumably because these prior studies suggest that UK5099 does not have 
an effect on astrocytes (Divakaruni et al., 2017;Weightman Potter et al., 2019). Nevertheless, 
applications of UK5099 to other cell types have successfully highlighted the compensatory 
mechanisms utilized for carbon entry into the mitochondria. These  compensatory mechanisms 
include upregulation of fatty acid oxidation (Vacanti et al., 2014), an increase in 
glutamate/glutamine metabolism (Vacanti et al., 2014;Yang et al., 2014;Gray et al., 2015), and 
pyruvate-alanine interconversion (McCommis et al., 2015). However, the cell types were not 
glycolytic or were highly proliferative, which is unlike astrocytes. Additionally, astrocytes are 
sensitive to ammonia toxicity caused by mitochondrial glutamine metabolism (Pichili et al., 
2007). Our preliminary BPTES results also indicate that glutaminase is not a vital process 
(Appendix Figure 2B). It is possible that by restricting a single mitochondrial carbon source, 
partial compensation could be achieved by upregulating the other mitochondrial carbon import 
pathways. This could be why the UK5099, etomoxir, and AOAA results had nearly equivalent 
effects on cell viability: the loss of one carbon source is compensated by the other sources.  
The effect of etomoxir could be an indicator that fatty acid oxidation (FAO) is vital. FAO 
is purported to be the source of acetyl-CoA, has already been demonstrated to be active in 
astrocytes (Edmond et al., 1987;Ebert et al., 2003), and astrocytes restrict pyruvate 
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dehydrogenase complex activity with extensive phosphorylation (Halim et al., 2010). FAO 
produces significant amounts of NADH and FADH2, which creates a need for an electron sink in 
order to maintain NAD+/NADH and FAD/FADH2 bioenergetic balancing. The role of the 
mitochondrial electron transport chain during arsenic exposure may be to maintain this 
bioenergetics balance. To further explore this hypothesis, we utilized Seahorse Mito Stress Test 
to determine the oxygen consumption rate of astrocyte mitochondria (Figure 4.7). In the presence 
of etomoxir and independent of arsenic, we observed minimal basal oxygen consumption and a 
minimal effect of oligomycin treatment. However, application of CCCP demonstrated that the 
electron transport chain was still functional and at a level similar to control cells. One possible 
interpretation is that the ETC normally acts to balance the bioenergetic disturbance of FAO, but 
the removal of mitochondrial FAO effectively eliminates the majority of the ETC’s purpose. 
However, arsenic exposure requires a mitochondrial process that uses glucose and fatty acid 
carbon inputs. Thus, the loss of FAO leads to the observed reduction in viability.  
Inhibition of transamination processes by AOAA causes a similar loss in viability during 
arsenic exposure as seen with UK5099 and etomoxir. However, transamination participates in 
both bioenergetic balancing and biosynthesis, and is not restricted to mitochondrial processes. 
Previous reports on astrocytes have shown that AOAA restricts the metabolism and synthesis of 
glutamate from TCA cycle intermediates (Westergaard et al., 1996;Sonnewald et al., 1997). 
Further studies highlighted that glutamine synthesis required aspartate (Pardo et al., 2011), further 
reinforcing the potential role of transamination for glutamate synthesis (McKenna et al., 2016). 
On the other hand, astrocytes upregulate glucose and lactate metabolism in the presence of 5 mM 
AOAA, indicating that the malate-aspartate shuttle is not the mechanism of electron balance in 
astrocytes (McKenna et al., 1993). This observation doesn’t outright disprove the hypothesis that 
the ETC is being used for bioenergetic balancing. The glycerol 3-phosphate shuttle has been 
implicated in astrocytes (McKenna et al., 1993;Waagepetersen et al., 2001), though more 
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verification is required due to discrepancies in the shuttle’s expression in astrocytes (McKenna et 
al., 2006). This argues in favor of our AOAA results being related to aminotransferase inhibition 
in regards to glutamate synthesis, and, therefore; that de novo glutamate synthesis is crucial for 
astrocyte viability. However, we did not observe a decrease in extracellular glutamate 
accumulation in the presence of AOAA (Figure 4.6E), which argues against this idea, but we did 
observe that AOAA increased arsenic accumulation within astrocytes (Figure 4.6D). This result 
indicates that a transamination process is involved in arsenic detoxification. 
While the glucose NMR results (Figure 4.2) require further analysis and supplemental 
experimentation to make definitive conclusions, we can speculate as to what the currently 
observed metabolite trends indicate. The reduction in UDP-glucose at all arsenic concentrations is 
an indication that glycogenesis is being downregulated in the presence of arsenic. This is 
supported by previous studies that described glucose consumption and lactate production to 
increase during acute arsenic toxicity (Tadepalle et al., 2014). While the intracellular lactate level 
did not significantly change (with the exception of the highest arsenic concentrations tested), we 
observed an increase in the extracellular lactate excretion at sublethal arsenic exposure. 
Extracellular citrate followed a similar trend as lactate, indicating that increased glucose 
utilization is feeding both cytosolic and mitochondrial pathways. Fructose-6-phosphate decreased 
at sublethal arsenic levels, remained equivalent at equilibrium concentrations, and rose at lethal 
doses. Conversely, 3-phosphoglycerate levels increased for all arsenic concentrations tested 
(Figure 4.2A). The 6-AN viability results (Figure 4.3A) suggest cytosolic NADPH is not a 
limiting resource during arsenic exposure. Metabolomic studies in other cell types studying ROS 
and PPP induction found that upper glycolysis intermediates (such as fructose-6-phosphate) 
increase, while lower glycolysis intermediates (such as 3-phosphoglycerate) decrease (Kuehne et 
al., 2015;Lucarelli et al., 2015). Since sublethal arsenic exposure exhibits an opposite trend and 
we did not identify changes in PPP intermediates, glycolysis may be preferred over PPP during 
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arsenic toxicity. However, that does not explain why the fructose-6-phosphate trend reverses at 
lethal arsenic concentrations.  
Interestingly, the preliminary glutamate NMR results (Appendix Figure 3) show that 
extracellular glutamate levels increased during arsenic exposure, which corroborates our findings 
from the glucose NMR (Figure 4.2) and the Glutamate-Glo experiments (Figure 4.5A and 
Figure 4.6E). The extracellular lactate levels did not change, indicating that glutamate 
metabolism did not change. Surprisingly, GSH levels did not increase with arsenic, which we 
would have expected given the requirement for GSH synthesis during arsenic exposure (Figure 
4.3B). It is possible that glutamate is not a limiting reagent for GSH synthesis (that it is cysteine 
instead), and that glutamate is being utilized for another, undefined process in astrocytes during 
arsenic exposure.  
 
4.5 Conclusions 
 We can conclusively demonstrate that arsenic detoxification in astrocytes requires GSH 
synthesis and MRP1. We also demonstrate that in the presence of arsenic, astrocytes synthesize 
glutamate from glucose precursors and efflux glutamate into the extracellular space to 
concentrations beyond what is considered the excitotoxicity threshold for most glutamatergic 
neurons. We further show that inhibition of EAAT1/2 causes an increase in extracellular 
glutamate independently of arsenic, and that EAAT1, but not EAAT2, inhibition sensitizes 
astrocytes to arsenic. Additionally, we demonstrate that the mitochondria perform a critical, yet 
undefined, function in astrocytes exposed to arsenic, and that inhibition of the mitochondrial 
pyruvate carrier or transamination processes sensitizes astrocytes to arsenic (Figure 4.8). 
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Figure 4.8: Essential Tested Metabolic Pathways during Arsenic Exposure 
Model of astrocyte metabolism. (A) Astrocytes remain viable during chemical inhibition of mitochondrial 
metabolism, and mechanisms of GSH synthesis and glutamate transport. (B) During arsenite exposure, 
mitochondrial metabolism, GSH synthesis, and glutamate transport become essential for survival, in 
addition to the activity of MRP1. Glutamate accumulates extracellularly to excitotoxic concentrations 
during arsenite exposure by a yet determined mechanism. (?): The role of transamination requires further 
characterization, and cannot be definitely linked to glutamate synthesis. 
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CHAPTER 5 
CONCLUSIONS AND FUTURE EXPERIMENTS 
 
 Chapters 2 and 3 provide in depth explorations of current literature highlighting the 
complexity and interconnectedness of the cells of the central nervous system, and the specialized 
metabolic functions of astrocytes, with an emphasis on mitochondrial function. In chapter 4, 
experiments were performed to explore the alteration of astrocyte metabolism when challenged 
with the xenobiotic arsenic. The results of these experiments show that astrocytes were shown to 
be dependent upon de novo glutathione (GSH) synthesis during arsenic exposure. A time course 
of intracellular arsenic accumulation at various arsenic concentrations illustrated that there was an 
acute phase accumulation of arsenic in astrocytes, followed by an adaptive chronic phase where 
arsenic accumulation was halted or reversed at sub-lethal sodium arsenite concentrations. Further, 
inhibition of the multidrug resistance protein 1 (MRP1) led to an accumulation of intracellular 
arsenic in astrocytes and sensitized astrocytes to arsenic. Arsenic exposure led to an accumulation 
of glutamate in the media of astrocyte cultures, an effect exacerbated by the inhibition of 
excitatory amino acid transporters 1 and 2 (EAAT1/2). Additionally, application of mitochondrial 
toxins or inhibition of carbon inputs to the mitochondria or transamination processes sensitized 
astrocytes to arsenic. The relevance of each of these results is briefly covered below. 
 Arsenic exposure requires de novo synthesis of GSH to maintain astrocyte viability, 
illustrating that the reduction of existing oxidized glutathione (GSSG) pools is insufficient to 
maintain astrocyte viability and REDOX homeostasis in the presence of arsenic. Cellular and 
DNA damage from reactive oxygen species (ROS) has been observed during arsenic exposure in 
other cell types (Hei et al., 1998;Liu et al., 2001). While low dose arsenic does not generate 
detectable ROS in viable astrocytes (Catanzaro et al., 2010), it should be noted that astrocyte 
intracellular GSH content does not significantly change at the same low doses after 24hrs (Zhao 
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et al., 2012). This thesis reinforces that arsenic induced ROS is not a significant factor by 
illustrating that 6-aminonicotinamide (6-AN), an inhibitor of the pentose phosphate pathway 
(PPP), has no significant effect on arsenic sensitization in astrocytes, while inhibition of GSH 
synthesis by L-buthionine-sulfoximine (BSO) profoundly sensitized the astrocytes to arsenic.  
 The generation of a time course of intracellular arsenic accumulation at low doses was 
important to illustrate that the detoxification mechanisms in astrocytes exposed to arsenic are not 
immediate, and that 10 µM sodium arsenite is near the limit of the detoxification capacity of 
astrocytes. The time-course generated in this thesis illustrates that within the first three hours of 
exposure, intracellular arsenic accumulation increases, followed by a reversal (5 µM sodium 
arsenite) or cessation (10 µM sodium arsenite) of arsenic accumulation beyond that point at sub-
lethal concentrations. The time course of 20 µM sodium arsenite does not clearly demonstrate 
such a change, and the astrocytes show cell death at 48hrs at this concentration.  Prior literature 
illustrates that arsenic accumulation measurements in astrocytes has used either very high arsenic 
concentrations (Koehler and Dringen, 2013;Koehler et al., 2014), and/or have used very short 
exposure times (Koehler and Dringen, 2013;Tadepalle et al., 2014). The time course created in 
this thesis demonstrates that cellular responses to xenobiotics clearly differ significantly over the 
exposure time (in hours for astrocytes and arsenic), and that metabolic changes due to xenobiotic 
exposure may be masked if assays are performed too quickly following exposure. Further, this the 
near steady state of intracellular arsenic accumulation in astrocytes at 10 µM sodium arsenite 
provide an experimental condition whereby disruptions to detoxification processes may be readily 
observed in terms of viability. 
 The results obtained from the inhibition of MRP1 provide further evidence in the 
contended role of this transporter in arsenic exposure. MRP1 has been described to efflux a 
glutathionylated arsenical complex (Leslie et al., 2004;Carew et al., 2011) (reviewed in (Leslie, 
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2012)), or to co-transport arsenic and GSH out of the cell (Salerno et al., 2002). MRP1 is also 
responsible for the neuroprotective export of GSH by astrocytes to neurons, reviewed in detail in 
Chapters 2 and 3. Studies into the effects of MRP1 inhibition by MK571 during arsenic exposure 
in astrocytes found that arsenic accumulation increased in the presence of MK571 but no effect 
on astrocyte viability was observed (Meyer et al., 2013;Tadepalle et al., 2014). A separate study 
found similar increases in arsenic accumulation with MK571, but observed cytotoxic effects as 
well after 72hrs (Gulden et al., 2017). Our data reinforce that MRP1 inhibition leads to an 
increase in intracellular arsenic accumulation and compromises cell viability. 
 During arsenic exposure, excitotoxic concentrations of glutamate accumulate in the 
media of astrocyte cultures. As detailed in chapter 4, NMR results show that glucose carbons are 
being metabolized toward the production of glutamate that principally is found in the media, 
rather than within the astrocytes. Further NMR experiments are underway to better isolate the 
precise metabolic pathways utilized for this glutamate production but were not ready at the time 
of this thesis. A previous report that found an approximate 1.5 µM increase in extracellular 
glutamate after 24hrs exposure of 10 µM sodium arsenite (Wang et al., 2012). An enzymatic 
assay was performed (see chapter 4) and the extracellular glutamate observed here was 
consistently above 30 µM. Glutamate is an excitatory neurotransmitter, and neuronal 
excitotoxicity has been observed in the 2-5 µM glutamate range (Lipton and Rosenberg, 
1994;Mark et al., 2001;Chen and Lipton, 2006). This finding has profound implications for 
neuronal survival when astrocytes are exposed to arsenic. An additional quantification technique 
beyond the enzymatic assay performed is warranted, given the similarity of this thesis’s 
methodology and that described above (Wang et al., 2012). Further, it is important to discover 
how this glutamate is released, as the mechanism may lie in a region of the astrocyte far from a 
synaptic cleft (see chapter 3 for more detail). Regardless, this is a novel finding. 
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 This thesis begins to explore two possible mechanisms for the release of glutamate from 
astrocytes. The first is by the cystine-glutamate exchanger (xCT), which effluxes glutamate to 
take in cystine, a rate limiting component of GSH synthesis. Viability experiments utilizing 
sulfasalazine (SAS), an inhibitor of xCT, showed a minor but significant reduction in astrocyte 
viability. Experiments are planned to test if SAS significantly impacts the accumulation of 
extracellular glutamate but were not completed at the time of this thesis. The second is by 
reversal of EAAT1 and EAAT2 (Szatkowski et al., 1990), transporters that normally are involved 
in the uptake of glutamate (see chapter 3 and 4). Inhibition of both EAAT1/2 significantly 
increased the extracellular glutamate concentration, including in the absence of arsenic. This data 
indicates that EAAT1/2 are not only not the source of glutamate release, but are also active to 
counteract some other mechanism of glutamate release that occurs during culture conditions, 
which requires further characterization. A test of extracellular glutamate quantification with 
EAAT1 and EAAT2 independently inhibited is planned for future tests. Viability tests of EAAT1 
and EAAT2 inhibition demonstrated that EAAT1 inhibition, but not EAAT2, sensitized 
astrocytes to arsenic, indicating that EAAT1 is playing a vital function during toxicity. One 
possibility is that intracellular glutamate is being depleted and must be synthesized from glucose 
and/or reuptaken by EAAT1 in order to maintain GSH synthesis.  
 Data from this thesis demonstrates that mitochondrial metabolism is required in 
astrocytes during arsenic exposure. As outlined in more detail in chapters 2-4, astrocytes are 
principally glycolytic, do not require oxidative phosphorylation to perform their functions, and 
are resistant to mitochondrial toxins (Bolanos et al., 1995;Almeida et al., 2001;Supplie et al., 
2017). This thesis confirmed that astrocytes remained viable in the presence of mitochondrial 
toxins, but these toxins sensitized the astrocytes to arsenic, indicating that the mitochondria are 
performing a vital function during arsenic exposure. The prior data from this thesis indicates that 
114 
 
it may be tied to glutamate synthesis from glucose (NMR results) to synthesize GSH (BSO 
results) and/or to compensate for the glutamate effluxed during arsenic exposure (NMR and 
Glutamate-Glo assay). To this end, inhibition of mitochondrial carbon inputs by UK5099, an 
inhibitor pyruvate entry to the mitochondria, and by etomoxir, an inhibitor of medium and long 
chain fatty acid entry to the mitochondria. Similarly, inhibition of transamination, a component of 
glutamate synthesis, by aminooxyacetic acid (AOAA) was tested. All three inhibitors (UK5099, 
etomoxir, AOAA) significantly decreased astrocyte viability in the presence of arsenic. The 
AOAA result indicates that a transamination process is involved in arsenic detoxification, and 
warrants further exploration, as transamination is not limited to mitochondrial processes. 
 Fatty acid utilization as a mitochondrial carbon source in astrocytes is a recent subject of 
research (see chapter 3), and the etomoxir results reinforce this possibility. To further characterize 
this, a Mitochondrial Stress Test (Agilent) was performed in the presence of etomoxir and 
arsenic. The co-administration of etomoxir and arsenic seems to cause major mitochondrial 
dysfunction with a drastically reduced mitochondrial capacity for OXPHOS. This could be a sign 
of mitochondrial degradation at this time point, and requires further exploration to determine the 
cause. It should be noted that a 200 µM etomoxir treatment may have off target effects, since 
etomoxir has been proposed to inhibit glutamine metabolism (O'Connor et al., 2018), to inhibit 
complex I activity (Yao et al., 2018), and to deplete the cell of CoA (Divakaruni et al., 2018). 
While the minimal basal activity of etomoxir may be due to complex I inhibition, the effect of 
etomoxir on maximal respiration was minimal. To test this, the Mitochondrial Stress Test should 
be repeated with just rotenone, or another complex I inhibitor, to see if the same effect was 
observed. Additionally, the test should also be performed with UK5099 and AOAA. 
 What is clear is that a complex process occurs in astrocytes to facilitate survival in the 
presence of the xenobiotic arsenic. This survival facilitation occurs in a time dependent manner 
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that was not clear from prior literature results, and involves both the synthesis of GSH as well as 
glutamate. Consequently, it appears that in adapting to survive in the presence of arsenic, 
astrocytes may produce a toxic environment for nearby neurons. While many facets of the 
metabolic response remain to be explored and characterized, it is clear that astrocytes depend 
upon the biosynthetic properties of mitochondria to survive. 
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APPENDIX A: Supplemental Figures 
 
Appendix Figure 1: Viable cell population determined by flow cytometry following 48hrs of hydrogen 
peroxide vs. 25µM MK571. a,b: p<.05 Two Way ANOVA vs. the untreated control (a) or the control at the 
same arsenic concentration (b). 
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Appendix Figure 2: (A-B) Viable cell population determined by flow cytometry following 48hrs of the 
indicated arsenic vs. (A) 200µM cystine, 200µM methionine, or (B) 2µM BPTES. a: p<.05 Two Way 
ANOVA vs. the untreated control (a). Note: BPTES results are preliminary, and only have 2 replicates. 
 
120 
 
 
Appendix Figure 3: Preliminary 2D-NMR (
1
H-
13
C) metabolomics performed on astrocytes treated with 
the indicated arsenic concentrations in DMEM containing 100µM U-
13
C/
15
N-glutamate for 24hrs. 
Extracellular (A) and intracellular (B) components were measured for each sample and represented as fold 
change compared to control.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
